

Quarterly Information - ITR

Diagnósticos da America S.A.

March 31, 2013

Contents

Company Data

Capital Stock Composition	1
Cash Earnings.....	2

Individual Quarterly information

Statement of Financial Position – Assets	3
Statement of Financial Position – Liabilities and Equity	4
Statement of Income.....	5
Statement of Comprehensive Income	6
Cash Flows	7

Statement of Changes in Equity

1/1/2013 to 3/31/2013.....	8
1/1/2012 to 3/31/2012.....	9
Statement of Value Added	10

Consolidated Quarterly information

Statement of Financial Position – Assets	11
Statement of Financial Position – Liabilities and Equity	12
Statement of Income.....	13
Statement of Comprehensive Income	14
Cash Flows	15

Statement of Changes in Equity

1/1/2013 to 3/31/2013.....	16
1/1/2012 to 3/31/2012.....	17
Statement of Value Added	18
Comments on the Company's Performance	19
Notes to Quarterly information	23

Reports and Representations

Independent auditor's review report on quarterly financial information	71
Opinions and Statements/Statement of Officers on the Financial Statements	73
Opinions and Declarations/Statement of Officers on the Independent Auditors Report	74

Company data / Capital Composition

Number of shares (Units)	Current quarter 03/31/2013
Paid-in capital	
Common shares	311,803,015
Preferred shares	0
Total	311,803,015
Treasury shares	
Common shares	1,159,035
Preferred shares	0
Total	1,159,035

Company Data / Cash Earnings

Event	Approval	Earnings	Initial Payment	Share	Class of Share	Earnings per share (Reais / Share)
Annual General Meeting	4/22/2013	Dividends	6/20/2013	Common		0.06600

Individual Financial Statements / Balance Sheet – Assets**(R\$ thousand)**

Code	Description	Current Quarter 03/31/2013	Previous Year 12/31/2012
1	Total assets	4,121,016	4,058,267
1.01	Current assets	705,989	663,079
1.01.01	Cash and cash equivalents	184,667	152,546
1.01.03	Accounts receivable	379,620	354,812
1.01.03.01	Trade accounts receivable	379,620	354,812
1.01.04	Inventories	34,740	39,460
1.01.06	Taxes recoverable	79,441	82,042
1.01.06.01	Current taxes recoverable	79,441	82,042
1.01.07	Prepaid expenses	968	789
1.01.08	Other current assets	26,553	33,430
1.01.08.03	Other	26,553	33,430
1.01.08.03.20	Other receivables	26,553	33,430
1.02	Non-current assets	3,415,027	3,395,188
1.02.01	Long-term receivables	143,273	154,430
1.02.01.01	Marketable securities at fair value	46,849	46,803
1.02.01.01.01	Marketable securities	46,849	46,803
1.02.01.07	Prepaid expenses	806	982
1.02.01.08	Receivables from related parties	4,000	15,500
1.02.01.08.02	Receivables from subsidiaries	4,000	15,500
1.02.01.09	Other non-current assets	91,618	91,145
1.02.01.09.04	Judicial deposits	91,590	91,117
1.02.01.09.05	Other non-current assets	28	28
1.02.02	Investments	431,214	401,915
1.02.02.01	Equity interest	430,590	401,554
1.02.02.01.02	Investments in subsidiaries	430,590	401,554
1.02.02.02	Investment properties	624	361
1.02.02.02.20	Others	624	361
1.02.03	Property and equipment	538,639	539,808
1.02.04	Intangible assets	2,301,901	2,299,035
1.02.04.01	Intangible assets	2,301,901	2,299,035

Individual Financial Statements / Balance Sheet – Liabilities**(R\$ thousand)**

Code	Description	Current Quarter 03/31/2013	Previous Year 12/31/2012
2	Total liabilities	4,121,016	4,058,267
2.01	Current liabilities	347,216	312,742
2.01.01	Social security and labor liabilities	71,147	59,409
2.01.02	Trade accounts payable	51,520	54,714
2.01.03	Tax liabilities	10,443	9,608
2.01.04	Loans and financing	106,600	91,325
2.01.04.01	Loans and financing	13,683	16,840
2.01.04.02	Debentures	92,917	74,485
2.01.05	Other liabilities	107,506	97,686
2.01.05.02	Other	107,506	97,686
2.01.05.02.01	Dividends and interest on equity payable	20,235	20,235
2.01.05.02.04	Taxes in installments	4,797	2,370
2.01.05.02.05	Accounts payable for acquisition of subsidiaries	1,618	1,598
2.01.05.02.06	Capital deficiency of subsidiaries	27,343	26,130
2.01.05.02.07	Financial instruments	936	763
2.01.05.02.08	Other payables	52,577	46,590
2.02	Non-current liabilities	1,143,372	1,138,715
2.02.01	Loans and financing	892,719	895,811
2.02.01.01	Loans and financing	7,907	11,312
2.02.01.02	Debentures	884,812	884,499
2.02.02	Other liabilities	70,061	68,440
2.02.02.02	Other	70,061	68,440
2.02.02.02.03	Taxes in installments	9,712	10,022
2.02.02.02.04	Accounts payable for acquisition of subsidiaries	55,876	57,002
2.02.02.02.05	Financial instruments	447	470
2.02.02.02.06	Other payables	4,026	946
2.02.03	Deferred taxes	49,702	45,538
2.02.03.01	Deferred income and social contribution taxes	49,702	45,538
2.02.04	Provisions	130,890	128,926
2.02.04.01	Provisions for tax, civil and labor risks	130,890	128,926
2.03	Equity	2,630,428	2,606,810
2.03.01	Paid-in capital	2,234,135	2,234,135
2.03.02	Capital reserves	48,266	48,171
2.03.02.02	Special reserve for goodwill on merger	65,427	65,427
2.03.02.04	Granted options	1,456	1,361
2.03.02.05	Treasury shares	-18,617	-18,617
2.03.04	Revenue reserves	323,091	322,933
2.03.04.01	Legal reserve	23,563	23,563
2.03.04.05	Retained profit reserve	299,259	299,101
2.03.04.08	Additional proposed dividend	269	269
2.03.05	Retained earnings	23,522	0
2.03.06	Other comprehensive income	1,414	1,571

Individual Financial Statements / Statement of Income**(R\$ thousand)**

Code	Description	Accumulated current year 01/01/2013 to 03/31/2013	Accumulated previous year 01/01/2012 to 03/31/2012
3.01	Revenue from products sold and/or services rendered	412,202	392,823
3.02	Cost of products sold and/or services rendered	-286,073	-256,871
3.03	Gross Profit	126,129	135,952
3.04	Operating income/expenses	-78,688	-59,483
3.04.02	General and administrative expenses	-95,071	-87,300
3.04.04	Other operating income	61	201
3.04.06	Equity pickup	16,322	27,616
3.05	Income before financial income/expenses and taxes	47,441	76,469
3.06	Financial income/expenses	-19,755	-32,060
3.06.01	Financial income	5,176	10,155
3.06.02	Financial expenses	-24,931	-42,215
3.07	Income before income and social contribution taxes	27,686	44,409
3.08	Income and social contribution taxes	-4,164	-8,039
3.08.02	Deferred	-4,164	-8,039
3.09	Net income from continuing operations	23,522	36,370
3.11	Net income for the period	23,522	36,370
3.99	Earnings per share (reais/share)		
3.99.01	Basic earnings per share		
3.99.01.01	Common shares	0.07572	0.11708
3.99.02	Diluted earnings per share		
3.99.02.01	Common shares	0.07564	0.11705

Individual Financial Statements / Statement of Comprehensive Income**(R\$ thousand)**

Code	Description	Accumulated current year 01/01/2013 to 03/31/2013	Accumulated previous year 01/01/2012 to 03/31/2012
4.01	Net income for the period	23,522	36,370
4.03	Comprehensive income for the period	23,522	36,370

Individual Financial Statements / Statement of Cash Flows**(R\$ thousand)**

Code	Description	Accumulated current year 01/01/2013 to 03/31/2013	Accumulated previous year 01/01/2012 to 03/31/2012
6.01	Net cash from operating activities	77,850	83,546
6.01.01	Cash from operations	72,911	76,083
6.01.01.01	Net income for the period	23,522	36,370
6.01.01.02	Depreciation and amortization	33,936	24,898
6.01.01.03	Restatement of contingencies	3,609	1,746
6.01.01.04	Deferred taxes	4,164	8,039
6.01.01.05	Restatement of interest and exchange variation on loans	19,343	26,950
6.01.01.06	Gain on sale of property and equipment	1,738	3,015
6.01.01.07	Stock-option plan	96	0
6.01.01.08	Equity pickup	-16,322	-27,616
6.01.01.10	Provision for disallowance and default	2,825	2,681
6.01.02	Changes in assets and liabilities	4,939	7,463
6.01.02.01	Increase in trade accounts receivable and other receivables	-27,633	-17,089
6.01.02.02	Decrease in inventories	4,720	10,506
6.01.02.03	Decrease in other current assets	9,299	21,906
6.01.02.04	Decrease (increase) in other non-current assets	-605	215
6.01.02.05	Decrease in trade accounts payable	-1,846	-5,739
6.01.02.06	Decrease in accounts payable and provisions	21,004	-2,336
6.02	Net cash used in investing activities	-38,719	-60,551
6.02.01	Additions to property and equipment	-27,588	-58,978
6.02.02	Additions to intangible assets	-11,131	-2,773
6.02.04	Interest on equity received	0	1,200
6.03	Net cash used in financing activities	-7,010	-118,626
6.03.02	Payment of loans	-6,286	-105,600
6.03.05	Interest payment	-724	-13,026
6.05	Increase (decrease) in cash and cash equivalents	32,121	-95,631
6.05.01	At beginning of period	152,546	156,978
6.05.02	At end of period	184,667	61,347

Individual Financial Statements / Statement of Changes in Equity – 01/01/2013 to 03/31/2013**(R\$ thousand)**

Code	Description	Paid-in Capital	Capital Reserve, Granted options and treasury shares	Income reserve	Retained earnings	Other comprehensive income	Equity
5.01	Opening balances	2,234,135	48,171	322,933	0	1,571	2,606,810
5.03	Adjusted opening balances	2,234,135	48,171	322,933	0	1,571	2,606,810
5.04	Transactions with shareholders	0	96	0	0	0	96
5.04.03	Granted options	0	96	0	0	0	96
5.05	Total comprehensive income	0	0	0	23,522	0	23,522
5.06	Net income for the period	0	0	0	23,522	0	23,522
5.06.04	Depreciation of deemed cost	0	0	157	0	-157	0
5.07	Closing balances	2,234,135	48,267	323,090	23,522	1,414	2,630,428

Individual Financial Statements / Statement of Changes in Equity – 01/01/2012 to 03/31/2012

(R\$ thousand)

Code	Description	Paid-in Capital	Capital Reserve, Granted options and treasury shares	Income reserve	Retained earnings	Other comprehensive income	Equity
5.01	Opening balances	2,234,135	46,810	259,204	0	2,199	2,542,348
5.03	Adjusted opening balances	2,234,135	46,810	259,204	0	2,199	2,542,348
5.05	Total comprehensive income	0	0	0	36,370	0	36,370
5.05.01	Net income for the period	0	0	0	36,370	0	36,370
5.07	Closing balances	2,234,135	46,810	259,204	36,370	2,199	2,578,718

Individual Financial Statements / Statement of Value Added**(R\$ thousand)**

Code	Description	Accumulated current year 01/01/2013 to 03/31/2013	Accumulated previous year 01/01/2012 to 03/31/2012
7.01	Revenue	457,529	435,438
7.01.01	Sales of goods, products and services	457,436	435,253
7.01.02	Other revenue	61	0
7.01.03	Income related to construction of own assets	0	201
7.01.04	(Reversal of) allowance for doubtful accounts	32	-16
7.02	Inputs acquired from third parties	-213,470	-199,637
7.02.01	Cost of products, goods and services sold	-155,300	-145,921
7.02.02	Materials, energy, third-party services and other	-58,170	-53,716
7.03	Gross value added	244,059	235,801
7.04	Retentions	-33,936	-24,898
7.04.01	Depreciation, amortization and depletion	-33,936	-24,898
7.05	Net value added produced	210,123	210,903
7.06	Transferred value added received	21,498	37,771
7.06.01	Equity pickup	16,322	27,616
7.06.02	Financial income	5,176	10,155
7.07	Total value added to be distributed	231,621	248,674
7.08	Distribution of value added	231,621	248,674
7.08.01	Personnel	106,859	94,962
7.08.02	Taxes, fees and contributions	52,915	53,272
7.08.03	Debt remuneration	48,325	64,070
7.08.04	Equity remuneration	23,522	36,370
7.08.04.03	Retained profits	23,522	36,370

Consolidated Financial Statements / Balance Sheet – Assets**(R\$ thousand)**

Code	Description	Current Quarter 03/31/2013	Previous Year 12/31/2012
1	Total assets	4,315,434	4,272,175
1.01	Current assets	1,039,112	993,438
1.01.01	Cash and cash equivalents	228,319	228,519
1.01.02	Marketable securities	31,296	31,953
1.01.02.01	Marketable securities at fair value	31,296	31,953
1.01.02.01.01	Securities for trading	31,296	31,953
1.01.03	Accounts receivable	552,888	498,455
1.01.03.01	Trade accounts receivable	552,888	498,455
1.01.04	Inventories	53,111	61,442
1.01.06	Taxes recoverable	144,633	138,462
1.01.06.01	Current taxes recoverable	144,633	138,462
1.01.07	Prepaid expenses	1,152	979
1.01.08	Other current assets	27,713	33,628
1.01.08.03	Other	27,713	33,628
1.01.08.03.20	Other receivables	27,713	33,628
1.02	Non-current assets	3,276,322	3,278,737
1.02.01	Long-term receivables	214,635	214,305
1.02.01.01	Marketable securities at fair value	57,859	57,635
1.02.01.01.01	Securities for trading	57,859	57,635
1.02.01.06	Deferred taxes	57,604	57,002
1.02.01.06.01	Deferred income and social contribution taxes	57,604	57,002
1.02.01.07	Prepaid expenses	806	982
1.02.01.09	Other non-current assets	98,366	98,686
1.02.01.09.04	Judicial deposits	95,735	95,274
1.02.01.09.05	Other non-current assets	2,631	3,412
1.02.02	Investments	873	516
1.02.02.02	Investment Properties	873	516
1.02.02.02.01	Other	873	516
1.02.03	Property and equipment	710,932	716,474
1.02.04	Intangible assets	2,349,882	2,347,442
1.02.04.01	Intangible assets	2,349,882	2,347,442

Consolidated Financial Statements / Balance Sheet – Liabilities**(R\$ thousand)**

Code	Description	Current Quarter 03/31/2013	Previous Year 12/31/2012
2	Total liabilities	4,315,434	4,272,175
2.01	Current liabilities	425,800	400,966
2.01.01	Social security and labor liabilities	93,292	81,191
2.01.02	Trade accounts payable	80,909	84,429
2.01.03	Tax liabilities	28,417	30,335
2.01.04	Loans and financing	131,711	119,005
2.01.04.01	Loans and financing	38,794	44,520
2.01.04.02	Debentures	92,917	74,485
2.01.05	Other liabilities	91,471	86,006
2.01.05.02	Other	91,471	86,006
2.01.05.02.01	Dividends and Interest equity payable	20,235	20,235
2.01.05.02.04	Taxes in installments	6,349	4,820
2.01.05.02.05	Accounts payable for acquisition of subsidiaries	1,618	1,598
2.01.05.02.07	Financial instruments	936	763
2.01.05.02.20	Other accounts payable	62,333	58,590
2.02	Non-current liabilities	1,258,787	1,264,017
2.02.01	Loans and financing	975,814	987,376
2.02.01.01	Loans and financing	91,002	102,877
2.02.01.02	Debentures	884,812	884,499
2.02.02	Other liabilities	97,248	97,260
2.02.02.02	Other	97,248	97,260
2.02.02.02.03	Taxes in installments	25,889	28,010
2.02.02.02.04	Accounts payable for acquisition of subsidiaries	66,887	67,834
2.02.02.02.05	Financial instruments	447	470
2.02.02.02.20	Other accounts payable	4,025	946
2.02.03	Deferred taxes	51,535	47,130
2.02.03.01	Deferred income and social contribution taxes	51,535	47,130
2.02.04	Provisions	134,190	132,251
2.02.04.01	Provisions for tax, civil and labor risks	134,190	132,251
2.03	Consolidated equity	2,630,847	2,607,192
2.03.01	Paid-in capital	2,234,135	2,234,135
2.03.02	Capital reserves	48,266	48,171
2.03.02.02	Special reserve for goodwill on merger	65,427	65,427
2.03.02.04	Granted options	1,456	1,361
2.03.02.05	Treasury Shares	-18,617	-18,617
2.03.04	Income reserves	323,091	322,933
2.03.04.01	Legal reserve	23,563	23,563
2.03.04.05	Retained profit reserve	299,259	299,101
2.03.04.08	Additional proposed dividend	269	269
2.03.05	Retained Earnings	23,522	0
2.03.06	Other comprehensive income	1,414	1,571
2.03.09	Non-controlling interest	419	382

Consolidated Financial Statements / Statement of Income**(R\$ thousand)**

Code	Description	Accumulated current year 01/01/2013 to 03/31/2013	Accumulated previous year 01/01/2012 to 03/31/2012
3.01	Revenue from products sold and/or services rendered	581,587	556,693
3.02	Cost of products sold and/or services rendered	-402,610	-360,217
3.03	Gross profit	178,977	196,476
3.04	Operating income/expenses	-121,703	-106,354
3.04.02	General and administrative expenses	-122,099	-106,928
3.04.04	Other operating income	396	574
3.05	Profit before financial income/expenses and taxes	57,274	90,122
3.06	Financial income/expenses	-20,994	-32,435
3.06.01	Financial income	8,053	16,527
3.06.02	Financial expenses	-29,047	-48,962
3.07	Income before income and social contribution taxes	36,280	57,687
3.08	Income and social contribution taxes	-12,720	-21,273
3.08.01	Current	-8,916	-9,750
3.08.02	Deferred	-3804	-11,523
3.09	Net income from continuing operations	23,560	36,414
3.11	Consolidated net income for the period	23,560	36,414
3.11.01	Attributed to controlling shareholders	23,522	36,370
3.11.02	Attributed to non-controlling shareholders	38	44
3.99	Earnings per share (reais/share)		
3.99.01	Basic earnings per share		
3.99.01.01	Common shares	0.07584	0.11708
3.99.02	Diluted earnings per share		
3.99.02.01	Common shares	0.07576	0.11705

Consolidated Financial Statements / Statement of Comprehensive Income**(R\$ thousand)**

Code	Description	Accumulated current year 01/01/2013 to 03/31/2013	Accumulated previous year 01/01/2012 to 03/31/2012
4.01	Consolidated net income for the period	23,560	36,414
4.03	Consolidated comprehensive income for the period	23,560	36,414
4.03.01	Attributed to controlling shareholders	23,522	36,370
4.03.02	Attributed to non-controlling shareholders	38	44

Consolidated Financial Statements / Statement of Cash Flows**(R\$ thousand)**

Code	Description	Accumulated current year 01/01/2013 to 03/31/2013	Accumulated previous year 01/01/2012 to 03/31/2012
6.01	Net cash from operating activities	60,807	76,255
6.01.01	Cash from operations	94,076	111,312
6.01.01.01	Net income for the period	23,560	36,414
6.01.01.02	Depreciation and amortization	41,810	32,258
6.01.01.03	Restatement of contingencies	3,609	1,746
6.01.01.04	Deferred taxes	3,804	11,523
6.01.01.05	Restatement of interest and exchange variation on loans	21,025	27,577
6.01.01.06	Gain on sale of property and equipment	1,674	3,014
6.01.01.07	Non-controlling interest	0	-98
6.01.01.08	Stock-option plan	96	0
6.01.01.10	Provision for disallowance and default	-1,502	-1,122
6.01.02	Changes in assets and liabilities	-25,980	-31,213
6.01.02.01	Increase in accounts receivable and other receivables	-52,931	-25,965
6.01.02.02	Decrease in inventories	8,331	13,133
6.01.02.03	(Increase) / decrease in other current assets	226	-28,903
6.01.02.04	Increase in other non-current assets	-84	-3,747
6.01.02.05	Decrease in trade accounts payable	-2,627	-8,440
6.01.02.06	Increase in accounts payable and provisions	21,105	22,709
6.01.03	Other	-7,289	-3,844
6.01.03.02	Income and social contribution taxes paid	-7,289	-3,844
6.02	Net cash used in investing activities	-41,276	-73,047
6.02.01	Additions to property and equipment	-30,075	-70,218
6.02.02	Additions to intangible assets	-11,201	-2,829
6.03	Net cash used in financing activities	-19,731	-115,734
6.03.01	Loans granted	0	7,274
6.03.02	Payment of loans	-17,764	-109,126
6.03.05	Decrease in cash and cash equivalents	-1,967	-13,882
6.05	Decrease in cash and cash equivalents	-200	-112,526
6.05.01	At beginning of period	228,519	249,945
6.05.02	At end of period	228,319	137,419

Financial Statements Consolidated / Statement of Changes in Equity– 01/01/2013 to 03/31/2013

(R\$ thousand)

Code	Description	Paid-in Capital	Capital Reserve – Granted options and treasury shares	Income reserve	Retained earnings	Other comprehensiv e income	Equity	Non-controlling interest	Consolidated Equity
5.01	Opening balances	2,234,135	48,171	322,933	0	1,571	2,606,810	382	2,607,192
5.03	Adjusted opening balances	2,234,135	48,171	322,933	0	1,571	2,606,810	382	2,607,192
5.04	Transaction with shareholders	0	96	0	0	0	96	0	96
5.04.03	Granted options	0	96	0	0	0	96	0	96
5.05	Total comprehensive income	0	0	0	23,522	0	23,522	37	23,559
5.05.01	Net income for the period	0	0	0	23,522	0	23,522	37	23,559
5.06	Internal changes in equity	0	0	157	0	-157	0	0	0
5.06.04	Depreciation of deemed cost	0	0	157	0	-157	0	0	0
5.07	Closing balances	2,234,135	48,267	323,090	23,522	1,414	2,630,428	419	2,630,847

Financial Statements Consolidated / Statement of Changes in Equity– 01/01/2012 to 03/31/2012**(R\$ thousand)**

Code	Description	Paid-in Capital	Capital Reserve, Granted options and treasury shares	Income reserve	Retained earnings	Other comprehensiv e income	Equity	Non-controlling interest	Consolidated Equity
5.01	Opening balances	2,234,135	46,810	259,204	0	2,199	2,542,348	-328	2,542,020
5.03	Adjusted opening balances	2,234,135	46,810	259,204	0	2,199	2,542,348	-328	2,542,020
5.05	Total comprehensive income	0	0	0	36,370	0	36,370	-54	36,316
5.05.01	Net income for the period	0	0	0	36,370	0	36,370	44	36,414
5.05.02	Other comprehensive income	0	0	0	0	0	0	-98	-98
5.05.02.06	Non-controlling interest	0	0	0	0	0	0	-98	-98
5.07	Closing balances	2,234,135	46,810	259,204	36,370	2,199	2,578,718	-382	2,578,336

Consolidated Financial Statements / Statement of Value Added**(R\$ thousand)**

Code	Description	Accumulated current year 01/01/2013 to 03/31/2013	Accumulated previous year 01/01/2012 to 03/31/2012
7.01	Revenue	640,793	610,102
7.01.01	Sale of goods, products and services	640,412	609,544
7.01.02	Other revenue	396	574
7.01.04	(Reversal of) allowance for doubtful accounts	-15	-16
7.02	Inputs acquired from third parties	-302,803	-269,720
7.02.01	Cost of products, goods and services sold	-223,056	-204,925
7.02.02	Materials, energy, third-party services and others	-79,747	-64,795
7.03	Gross value added	337,990	340,382
7.04	Retentions	-41,810	-32,258
7.04.01	Depreciation, amortization and depletion	-41,810	-32,258
7.05	Net value added produced	296,180	308,124
7.06	Transferred value added received	8,053	16,527
7.06.02	Financial income	8,053	16,527
7.07	Total value added to be distributed	304,233	324,651
7.08	Distribution of value added	304,233	324,651
7.08.01	Personnel	143,549	129,381
7.08.02	Taxes, fees and contributions	79,277	84,456
7.08.03	Debt remuneration	57,847	74,400
7.08.04	Equity remuneration	23,560	36,414
7.08.04.03	Retained profits	23,522	36,370
7.08.04.04	Non-controlling interest	38	44

Comments on the Company's Performance

Dear shareholder,

In this first quarter of 2013 ("1Q13"), the initiatives taken in 2012 are yielding results. Despite the smaller number of days, since we had 3 days less in relation to the first quarter of 2012, growth is at a faster pace. In terms of business days, the period was 5% shorter. Medical relationship, especially in São Paulo, is being strengthened and already shows promising results.

Our efforts are focused on ensuring an organic growth, strengthening the business segments where we operate, improving our services, reinforcing our knowledge and technical quality, as well as aligning our people with DASA Culture, thus reducing our employee turnover. Accordingly, we believe that the Company continuously moves on towards worldwide recognition for its quality and efficiency in diagnostic medicine, provision of services to all segments of the population and remuneration to shareholders.

Gross operating income

DASA's consolidated gross income in 1Q13 totaled R\$ 640.4 million, representing a 5.1% increase compared to 1Q12, which is mainly a consequence of the full-fledged development of the projects implemented throughout 2012, as well as of the industry organic growth, service portfolio optimization and expansion of the service agenda.

Considering DASA's gross income by service line, the hospital market had the best performance for the quarter, reporting revenue of R\$ 61.0 million, i.e. a 12.5% growth compared to 1Q12, which represents 9.5% of DASA's total income.

Income of the Outreach Clinic market totaled R\$ 471.3 million, 4.4% higher compared to 1Q12, which represents 73.6% of DASA's income.

The public market revenue totaled R\$ 43.7 million, with a 0.3% decrease in 1Q13, which represents 6.8% of DASA's income.

The Support segment revenue totaled R\$ 64.4 million, growing 7.5% vis-à-vis 1Q13, which represents 10.1% of DASA's total income.

Costs and gross income

In 1Q13, service costs totaled R\$ 402.6 million, equivalent to 69.2% of the net revenue. This percentage represents a growth of 11.8% comparatively with the costs in the first quarter of the prior year. In 1Q13, gross income was R\$ 179.0 million, decreasing 8.9% in relation to the same prior-year period.

Operating expenses

Operating expenses totaled R\$ 121.7 million in 1Q13, equivalent to 19.0% of the net income. Compared to the first quarter of 2012, there was a 14.4% increase, since they represented 19.1% of net income in that quarter.

EBITDA

In 1Q13, our EBITDA totaled R\$ 99.1 million, representing a 19.0% decrease in relation to the amount of R\$ 122.3 million in the same prior-year period. In 1Q13 we reached a margin of 17.0%. We are still committed to fully integrating the acquisitions made, optimizing production and administrative areas, and making continuous cost-cutting efforts by means of a management focused on sound results, and capable of generating sustainable shareholders' value.

Financial income (expenses)

In 1Q13, the amount of R\$ 21.0 million was recorded in net financial expenses, compared with R\$ 32.4 million in 1Q12. The decrease in financial expenses was mainly affected by the decrease in SELIC benchmark rate.

Taxes

Taxes totaled R\$ 12.7 million in the quarter. We are relying on the benefit stemming from the amortization of goodwill from acquisitions made in the previous periods.

Net income

In this quarter, net income totaled R\$ 23.5 million, 35.3% lower as compared to the R\$ 36.4 million income reported for the same prior-year period.

Cash and marketable securities

We ended the quarter with a cash and marketable securities position of R\$ 259.6 million, which will be allocated to: ensure expansion and modernization of the existing units, opening of new units and replacement of image equipment, as well as higher investments to improve quality.

Investments

Net CAPEX investments in 1Q2013 totaled R\$ 42.0 million. This year, investments will be mainly allocated to: (i) implementation and development of production and service systems, as well as renewal of the technology park, (ii) maintenance and expansion of the existing service units and construction of new units, (iii) purchase of image equipment.

Indebtedness

DASA net debt totaled R\$ 849.3 million in 1Q13. 88% of the gross indebtedness is allocated for the short-term and 7.1% refer to loans raised in foreign currency. Debt in foreign currency mainly refers to financing of equipment and International Notes. Debt in local currency is mainly related to Debentures, Promissory Notes and Lease transactions.

Material events for the quarterElection of Officers

On January 9, 2013, Antônio Carlos Gaeta became the Business VP, and Lilian Cristina Pacheco Lira became Legal Officer, both at statutory level.

On February 7, 2013, Cynthia May Hobbs Pinho was elected Executive VP and CFO.

The position currently held by Carlos Elder Maciel de Aquino was changed from Officer with no specific title to Chief Accounting and Infrastructure Officer.

Approval from the Administrative Council for Economic Defense (CADE) – Cytolab

On February 20, 2013, CADE approved the Merger Review Process (“AC”) No. 08012.007540/2011-58 referring to acquisition of Cytolab - Laboratório de Anatomia Patológica, Citopatologia Diagnóstica e Análises Clínicas Ltda., having only mandated a change in the geographic scope of the non-competition clause agreed upon with sellers. The Company will take the adequate measures to meet CADE determination within the prescribed period.

Subsequent eventsElection of the Board of Directors

Having the matter duly examined, the shareholders attending the Annual General Meeting (AGM) held on April 22, 2013 approved, in accordance with the voting system set out in paragraph 1 of Article 17 of the Company's charter, by their majority of votes, the candidates presented by Management on April 4, 2013, with the subsequent election of the Board of Directors, as follows:

(a) Romeu Côrtes Domingues, Chair of the Board of Directors; (b) Oscar de Paula Bernardes Neto, Vice Chair of the Board of Directors; (c) Dickson Esteves Tangerino, Board member; (d) Carlos Fernando Costa, Board member; (e) Maurício Bittencourt Almeida Magalhães, Board member.

Pursuant to the second paragraph of Article 17 of the Company's charter and the BM&FBOVESPA Novo Mercado Listing Regulation, Officers Oscar de Paula Bernardes Neto, Carlos Fernando Costa and Maurício Bittencourt Almeida Magalhães are considered independent under *Novo Mercado* ('New Market') Listing regulation.

Statutory Audit Committee (CAE)

The Special General Meeting (SGM), held on April 22, 2013, approved the set up of the Statutory Audit Committee (CAE) under the terms of CVM Rule No. 509/2011. At the Board of Directors' meeting, held on April 22, the Officers elected the following people as CAE members for a 10 (ten) year term: (i) Mr. Raimundo Lourenço Maria Christians; (ii) Mr. Maurício Bittencourt Almeida Magalhães, (iii) Mr. Raphael Nascimento Diederichsen; and (iv) Mrs. Manuela Cristina Lemos Marçal.

Reelection of the Company's current Management Board

The Board of Directors' Meeting held on April 22 decided– without any qualifications – to reelect the Company's Management Board members, with a unified term of office up to the AGM approving the accounts for the year ended December 31, 2015. The respective Management members are: (a) CEO: Mr. Dickson Esteves Tangerino; (b) VP Chief Operating Officer: Octávio Fernandes da Silva Filho; (c) VP Business Officer: Mr. Antonio Carlos Gaeta; (d) Chief Investors Relation Officer: Mr. Paulo Bokel Catta-Preta; (e) VP and CFO: Mrs. Cynthia May Hobbs Pinho; (f) Chief Personnel Officer: Mr. Marcelo Rucker; (g) Chief Account and Infrastructure Officer: Mr. Carlos Elder Maciel de Aquino; (h) Chief Radiology and Graphic Methods Officer: Mr. Emerson Leandro Gasparetto; (i) Legal Officer: Mrs. Lilian Cristina Pacheco Lira.

São Paulo State Installment Payment Program

São Paulo State Decree No. 58811/12 created a special State VAT (ICMS) payment program providing for elimination of 75% of fines and 60% of interest upon cash payment referring to ICMS debts, with a potential 45% additional reduction on fines in case of debts claimed but not under the federally enforceable debt, and a 5% reduction on attorney's fees in case of federally enforceable debts.

Considering these favorable conditions, the Company elected to enjoy these benefits and adhered to the program from May 6 to May 10 to pay off its debts not yet claimed, considered of probable risk by our legal counsel, and which are the subject of Injunction Relief No. 0046827-27.2011.8.26.0053, therefore eliminating tax contingencies referring to ICMS on imports and recorded under provision accounts for judicial deposits (Note 21).

The Company elected to pay ICMS debts in full, amounting to R\$ 38,213 (already with the benefits set out by the referred to Decree).

Outlook for 2013

In 2013, DASA is reinforcing its medical relationship program with an expansion in operations over 50%, compared with the prior year.

Furthermore, we already submitted 68 projects for approval at the 2013 AACCC (American Association for Clinical Chemistry), and we are attending the Second International Diagnostic Medicine Conference, to be held under our Delboni Auriemo brand. More than 200 other medical events to be held or supported by us in Brazil in 2013 have been scheduled.

In 1Q13, the Patient Magazine (*Revista do Paciente*) was launched. The first issue was published in March by brands Delboni Auriemo, Sergio Franco and CDPI, and this is yet another channel to keep the patient informed on the new technologies, physicians hired, events held, new units, enabling close communication with our customers.

All investments in modernization of the existing units, opening of new units, replacement of image equipment together with increased investments in quality improvement will ultimately provide for an environment of growth. This year, we will be implementing a unified customer service, scheduling and collection system which will not only improve our services, but also have a positive impact on our collection procedures.

We keep focused on improving our call center operations in order to maximize image equipment agenda and increase the productivity of our customer service units.

Arbitration clause

Any arbitration is to be held at the Market Arbitration Chamber, in accordance with the arbitration clause set forth in the Company's charter.

Projections and non-accounting data

The statements herein related to business perspectives, projections of operating and financial results and those related to the Company's expected growth merely correspond to projections and, as such, they are based solely on management's expectations on our business future. This performance report also includes accounting and non-accounting data, such as operating, financial data, as well as projections based on the Company's management expectations. Non-accounting data, including EBITDA was not reviewed by the Company's independent auditors.

Notes to the quarterly information

Management Representation

In accordance with the provisions of CVM Rule No. 480, we represent that we have discussed, reviewed and agreed with the financial statements and the independent auditor's report on quarterly information for the period ended March 31, 2013.

Acknowledgements

We would like to thank our employees for their concerted efforts, commitment and talent which enabled us to achieve such promising results, and also our customers and shareholders for the trust placed on us.

Notes to the quarterly information**1. Operations**

Diagnósticos da América S/A (Company) is a publicly-held corporation located in the city of Barueri, São Paulo State, with its registration granted by the Brazilian Securities Commission (CVM) for the trading of its securities on the stock market on November 5, 2004, and has been listed on the Novo Mercado segment of Bovespa since November 19, 2004, under code DASA3.

The Company's business purpose is to render services directly to individuals or through health insurance plans, insurance companies, medical-hospital assistance entities, other entities for healthcare financing, in the following areas: (i) clinical analysis, directly or through contracted laboratories; and (ii) other auxiliary diagnostic support services (SAD), exclusively through specialized clinics, as, for instance, in the following areas: a) cytology and pathologic anatomy; b) diagnostic by imaging and graphic methods; and c) nuclear medicine. As Management does not control them separately in their business process, they are not being recognized as reportable segments.

In addition, it explores activities related to: (i) tests in food and substances to evaluate risks for the human being; (ii) import, for its own use, of medical-hospital equipment, sets for diagnostics and related material in general; (iii) preparation, edition, publishing and distribution of newspapers, books, magazines, periodicals and other written media on scientific researches and activities developed by the Company; (iv) granting and administration of business franchising including advertising and publishing fund, training and selection of labor, supplying of equipment and research material suppliers, among others. The Company operates in lab-to-lab business (support to laboratories) through the Álvaro brand, and began offering services in the public health sector through the CientíficaLab brand. The Company can also hold equity interest in other entities.

Notes to the quarterly information

The Company ended the quarter with 521 operating units:

Marcas	Estado	03/31/13	12/31/12
Delboni Auriemo (i)	São Paulo	42	41
Lavoisier	São Paulo	76	81
Bronstein	Rio de Janeiro	42	42
Lâmina (i)	Rio de Janeiro	14	13
Pasteur	Brasília	25	23
Frischmann	Paraná	39	42
Image	Bahia	4	4
Laboratório Álvaro	Paraná	14	14
LabPasteur	Ceará	18	18
Vita-Lâmina	Santa Catarina	2	2
Atalaia	Goiás	21	21
Exame	Brasília	24	22
MedImagem	Rio de Janeiro	7	7
Hospital Mãe de Deus	Rio Grande do Sul	2	2
Cedic/Cedilab	Mato Grosso	11	11
Unimagem	Ceará	1	1
CERPE	Pernambuco	39	40
Sérgio Franco	Rio de Janeiro	78	78
Proecho	Rio de Janeiro	15	15
Multi Imagem	Rio de Janeiro	6	6
CDPI	Rio de Janeiro e São Paulo	7	7
Previlab	São Paulo	18	19
Cytolab	São Paulo	13	12
Alta Excelência Diagnóstica - <i>Premium</i>	São Paulo	3	2
		521	523

(i) The Club DA brand had 23 units on march 31, 2013, 19 of which linked to the Delboni Auriemo brand and 4 units related to the Lâmina brand.

Additionally, CientíficaLab operates in the public healthcare segment, and its major sources of revenue are the contracts formalized with customers in the public healthcare sector. This operation ended the first quarter 2013 with 24 customers, which made 1,5 million exam requisitions. CientíficaLab serves customers at 589 collection points, of which 83 Inpatient and 505 outpatient clinics, which are not included in the units listed above.

The information listed above is not included in the auditor's review scope.

Notes to the quarterly information**2. Agreement on Preservation of Reversibility of Operation (“APRO”)**a) Agreement on Preservation of Reversibility of Operation (“APRO”)

On October 26, 2011, the Company and the Administrative Council for Economic Defense (“CADE”) executed an Agreement on Preservation of Reversibility of Operation, in the case records of Concentration Act nº 08012.010038/2010-43, an Agreement to Preserve Reversibility of Transactions (“APRO”), referring to the subject matter of the Contract of Association executed on December 7, 2010, for acquisition of MD1 Group companies (“Transaction”), upon direct acquisition and purchase of shares, as approved in the Special General Meeting held on January 5, 2011. The purpose of APRO is to prevent, until the judgment of merit of the Concentration Act and relating to the companies that are the subject matter of the Operation (MD1 Group), irreversible amendments or amendments of difficult reparation, thus ensuring the reversibility of the Operation in the event that, upon judgment of the merits, CADE understands that the imposition of restrictions will be necessary. The execution of the APRO does not imply that CADE will be bound by the analysis of the merit or any anticipation related to the result of this judgment, nor does it bind the Company to reverse the integration measures adopted prior to its execution.

As provided for in the APRO, the Company engaged an independent auditor, BDO RCS Auditores Independentes, to attest to the fulfillment of the Agreement. In all bi-monthly reports already issued by BDO, the auditors concluded that all the requirements set forth in the APRO regarding the obligations to be fulfilled by the parties have been complied with.

Based on the opinion of its legal counsels, the Company concluded that, for purposes of compliance with the information disclosure obligations provided for in ICVM 480, DASA is not a related party of the companies of Amil Group, given that such companies are not controlled by and do not control DASA, are not under common direct or indirect control and their controllers have no material influence on DASA.

The Economic Supervision Office of the Ministry of Finance (SEAE) issued, on March 5, 2012, technical opinion No. 06145/2012/RJ regarding the Concentration Act entered into between Diagnósticos da América S/A and MD1 Diagnósticos S/A. The document, which contains merely an opinion, recommends the approval of the operation taking into account the restrictions detailed therein. The issuance of said opinion does not imply any binding of CADE to the analysis of the merit or anticipation of the results of the judgment of the operation by this body. The opinion issued by the SEAE is, apparently, based on assumptions of partial data regarding the interpretations given to the corporate relationship maintained between DASA, the individuals linked to JHSPE Empreendimentos and its subsidiaries, Amil Participações S.A and its subsidiaries, and FMG Empreendimentos Hospitalares. The technical opinion is available on the Internet, at

<http://www.fazenda.gov.br/littera/pdf/08012010038201043.pdf>

SEAE's opinion will not reverse the integration measures adopted as of the date of execution of the APRO, such as the merger of MD1 Participações Ltda. into the Company. The operation is still being analyzed by the CADE, and the Company maintains an active cooperation towards the positive results of the judgment. In this context, we are certain that the CADE will be able to make an appropriate and careful analysis of the market data and the corporate relationships existing between some shareholders and third parties, so as to conclude that the operation does not involve competition concerns, contrary to what is suggested by SEAE's opinion.

Notes to the quarterly information

Particularly, we understand that the CADE will analyze two relevant events that took place after the issuance of SEAE's opinion: the termination of the indirect corporate relationship between FMG Empreendimentos Hospitalares and Amil Participações S.A., as per the material fact announced by the latter on September 25, 2012; and ii) the disposal of share control of Amil Participações S.A. by some individual shareholders linked to JHSPE Empreendimentos to the UnitedHealth Group Incorporated (UHG), as disclosed to the market through the material fact issued on October 8, 2012 by Amil Participações S.A. The Company understands that these facts relevantly affect the interpretations included in SEAE's opinion on the operation and provide a positive contribution to the analysis of competition matters.

The Company is also certain that CADE will analyze the pro-competition effects of the operation, which would bring significant efficiency to the sector of auxiliary diagnostic support services. The Company will continue to offer active cooperation to CADE, looking forward to its approval in a timely manner.

3. Consolidation procedures

The Quarterly information comprises the statements of the Company and the following subsidiaries:

	% Equity in consolidation	
	Mar. 31, 2013	Dec. 31, 2012
Direct subsidiaries:		
DASA Real Estate Empreendimentos Imobiliários Ltda.	99.99%	99.99%
CientificaLab Produtos Laboratoriais e Sistemas Ltda.	99.99%	99.99%
DASA Finance Corporation	100.00%	100.00%
Instituto de Endocrinologia e Medicina Nuclear do Recife S.A. (CERPE)	100.00%	100.00%
DASA Log Empreendimentos Ltda.	99.00%	99.00%
DASA Sudoeste Participações Ltda.	99.00%	99.00%
DASA Nordeste Participações Ltda.	99.00%	99.00%
DASA Centro-Oeste Participações Ltda.	99.00%	99.00%
DASA Property Participações Ltda.	99.00%	99.00%
Pro Echo Cardiodata Serviços Médicos Ltda.	69.58%	69.58%
CRMI - Clínica de Ressonância e Multi Imagem Ltda.	99.99%	99.99%
CDPI - Clínica de Diagnóstico por Imagem Ltda.	99.99%	99.99%
Laboratórios Médicos Dr.Sérgio Franco Ltda.	99.99%	99.99%
Previlab Análises Clínicas Ltda.	99.56%	99.56%
Indirect subsidiaries:		
Pro Echo Cardiodata Serviços Médicos Ltda.	30.42%	30.42%
Clínica de Ressonância e Multi-Imagem Caxias Ltda.	99.99%	99.99%
Clínica de Ressonância e Multi-Imagem Petrópolis Ltda.	70.00%	70.00%
Imagem e Diagnóstico Ltda.	99.99%	99.99%
Check-Up UP - Unidade Prevent., Diagn. e Medicina Preventiva Ltda.	99.99%	99.99%
INCEBRAS Instituto Brasileiro da Coluna e do Cérebro Ltda.	29.00%	29.00%
Multimagem PET S/A.	100.00%	100.00%
STAT Análises Clínicas Ltda.	99.66%	99.66%

Notes to the quarterly information

4. Basis for preparation of financial statements

4.1. Declaration of conformity (in relation to IFRS and CPC standards)

The Quarterly information includes:

- The consolidated Quarterly information prepared in accordance with the International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB) and with the accounting practices adopted in Brazil, which follow the accounting pronouncements issued by the Accounting Pronouncements Committee (CPC); and
- The individual Quarterly information of the parent Company were prepared according to the accounting practices adopted in Brazil, which follow the accounting pronouncements issued by the Accounting Pronouncements Committee (CPC).

The individual Quarterly information of the parent Company were prepared in accordance with the accounting practices adopted in Brazil. Regarding the Company, these practices differ from the IFRSs applicable to the separate Quarterly information due to the measurement of investments in subsidiaries through the equity pick-up method required by the accounting practices adopted in Brazil, while, for purposes of the IFRS, such measurement would be made at cost or fair value. However, the Company's equity and consolidated income does not differ from the equity and income stated in the individual Quarterly information of the parent Company.

The publication of the individual and consolidated Quarterly information was authorized by the Board of Directors at the meeting held on May 13, 2013.

4.2. Basis for measurement

The individual and consolidated Quarterly information were prepared on the basis of historical cost, with except for the following items recognized in the statement of financial position: (i) derivative financial instruments measured at fair value; and (ii) non-derivative financial instruments measured at fair value thought profit or loss.

4.3. Functional and reporting currency

The individual and consolidated Quarterly information are presented in Reais (R\$), which is the Company's functional currency, all financial information presented in Reais was rounded off to the nearest thousand, except when otherwise indicated.

4.4. Use of estimates and judgment

The preparation of the individual and consolidated Quarterly information in accordance with IFRS and CPC standards requires Management to make judgments, estimates and assumptions that may affect the application of accounting policies and the reported values of assets, liabilities, revenue and expenses. Actual results may differ from such estimates.

Estimates and assumptions are permanently reviewed. Reviews relating to accounting estimates are recorded in the period in which the estimates are reviewed, as well as in any other future periods affected.

Notes to the quarterly information

Uncertainties about the assumptions or estimates that may pose significant risks of material adjustments in the following reporting period are detailed in the following notes:

- Note 9 - Trade accounts receivable
- Note 21 - Provision for tax, social security, labor and civil risks
- Note 25 – Assumptions used for determining the fair value of financial instruments.

4.5. Segregation between current and noncurrent

Except for deferred taxes, the Company segregated all equity items that are expected to be realized within twelve months as from the date of the Quarterly information as current.

4.6. Statement of comprehensive income

There were no equity transactions resulting in adjustments that might be recorded in the statement of comprehensive income, that is, income for the period equals comprehensive income.

5. Significant accounting practices

The Company represents that the quarterly information (ITR) is presented in accordance with the accounting practices presented in Note 5 of the financial statements for the year ended December 31, 2012.

The pronouncements CPC 19 (R2), CPC 36 (R3), CPC 45, CPC 46, applicable as from 2013, did not cause any impact on the Company's quarterly information.

6. Determination of fair values

A number of the Company's accounting policies and disclosures require the determination of fair value, for financial and non-financial assets and liabilities. The fair value has been calculated for measurement and/or disclosure purposes, consistently with the methods described in Note 6 of the financial statements for the year ended December 31, 2012, and must be analyzed together with these financial statements. Additional information on assumptions used for determination of fair value is disclosed in specific notes of the respective assets or liabilities, where applicable.

7. Cash and cash equivalents

	Company		Consolidated	
	03/31/13	12/31/12	03/31/13	12/31/12
Cash and banks	7,599	12,669	11,380	16,087
Marketable securities	177,068	139,877	216,939	212,432
	184,667	152,546	228,319	228,519

Notes to the quarterly information

Cash and cash equivalents classified in consolidated current assets are presented below:

	3/31/13		12/31/12	
	Amount	Average interest rate	Amount	Average interest rate
Cash and banks	11,380		16,087	-
Bank Deposit Certificate (CDB) / Committed transactions	50,621	103.89% of CDI		103.66% of CDI
Fixed income fund	166,318	103.24% of CDI	212,432	
	<u>228,319</u>		<u>228,519</u>	

Bank deposits represent balances in banks and immediate liquidity rights of which the use is not subject to any restrictions.

Short-term investments are readily redeemable from the issuer into a known cash amount and are subject to insignificant risk of change in value.

8. Marketable securities

	Company	Company			
		03/31/2013		12/31/2012	
		Currency	Amount in R\$	Average interest rate	Amount in R\$
CDB / Committed transactions	R\$	15,277	100.00% of CDI		
Fixed income fund (a)	R\$	31,572	103.29% of CDI	46,803	102.63% of CDI
		<u>46,849</u>		<u>46,803</u>	
Current assets		-		-	
Non-current assets		<u>46,849</u>		<u>46,803</u>	

	Consolidated	Consolidated					
		03/31/2013			12/31/2012		
		Currency	Amount in US\$	Amount in R\$	Average interest rate	Amount in US\$	Amount in R\$
CDB / Committed transactions	R\$	-	17,085	100.00% of CDI	-	-	-
Fixed income fund (a)	R\$	-	40,774	103.29% of CDI	-	57,635	101.70% of CDI
Brazilian public debt security	US\$	9,130	18,385	2.10% p.a.	9,515	19,443	1.76% p.a.
Private securities	US\$	6,411	12,911	5.18% p.a.	6,122	12,510	4.74% p.a.
			<u>89,155</u>			<u>89,588</u>	
Current assets			<u>(31,296)</u>			<u>(31,953)</u>	
Non-current assets			<u>57,859</u>			<u>57,635</u>	

(a) The consolidated amount of R\$57,859 (57,635 at December 31, 2012) invested in fixed income funds and CDB / Committed transactions corresponds to guarantee for payment of contingencies that may be demanded from acquired companies, for a period of up to 6 years from the date of acquisition.

Notes to the quarterly information**9. Trade accounts receivable**

	Company		Consolidated	
	03/31/13	12/31/12	03/31/13	12/31/12
Current				
Trade bills receivable:				
Falling due	243,113	216,209	347,592	288,535
Overdue (b)	166,568	178,985	212,394	230,834
	409,681	395,194	559,986	519,369
Other accounts receivable:				
Checks in collection	1,804	1,461	3,157	2,134
Credit Card	2,022	1,458	4,251	3,434
Unbilled services (a)	60,929	48,690	93,212	82,738
	64,755	51,609	100,620	88,306
Total receivables:	474,436	446,803	660,606	607,675
Less:				
Allowance for doubtful accounts due to disallowance, default and NSF checks	(94,816)	(91,991)	(107,718)	(109,220)
	(379,620)	354,812	(552,888)	498,455

(a) Refers to amounts of services rendered and not yet billed until to the closing of the quarter. Services not billed within 120 days are written off from account Agreements to be billed.

(b) The aging of overdue balances is presented below:

	Company		Consolidated	
	03/31/13	12/31/12	03/31/13	12/31/12
0 to 30	29,179	37,344	42,311	51,618
31 to 60	12,369	18,731	20,603	24,803
61 to 90	9,707	11,787	16,609	18,391
91 to 120	10,656	10,849	14,063	16,105
121 to 180	14,370	12,713	17,457	17,453
181 to 360	25,482	22,359	30,370	29,140
Above 360	64,805	65,202	70,981	73,324
	166,568	178,985	212,394	230,834

The collection process for diagnostic support services provided by the Company is complex due to a variety of factors, including the large number of health plans used and different coverage offered. This complexity has historically given rise to loss due to disallowances. To a lesser extent, there are also losses due to default.

Disallowances mainly refer to: (i) operating issues, such as services rendered to customers of health care plans without previous authorization; (ii) sales issues, such as new price lists agreed, which have not been updated on both systems; and (iii) technical issues, such as different interpretations of examination requisitions.

Notes to the quarterly information

To cover the losses as a result of such disallowances and default, Management adopts the policy of recording a provision for losses from disallowances and default based on receivables overdue for more than 90 days, as shown below:

<u>Overdue receivables:</u>	<u>% of provision</u>
91 and 120 days	25%
121 and 180 days	50%
181 and 360 days	75%
Above 360 days	100%

Beginning 2012, the Company has been writing off receivables overdue for more than 2 years against the provision. In the first quarter of 2013, according to this criteria, the amount of R\$ 6,810 (R\$ 19,563 at December 31, 2012) was written off.

The Company also adopts the criterion to set up an allowance for 100% of NSF checks, which, at March 31, 2013, corresponds to the amount of R\$1,048 (R\$1,080 at December 31, 2012) – Company, and R\$ 1,714 (1,699 at December 31, 2012) - Consolidated.

Due to the history of full credit card amounts received, the Company sets no provision for losses under this heading.

Changes in allowance for doubtful accounts due to disallowances, default and NSF checks in 2013 first quarter were consolidated as follows:

Balance at December 31, 2012	<u>(109,220)</u>
Additions	
Provision for and losses from disallowances and default	(20,535)
Reversal and write off	
Reversal of provision for disallowances, default and disallowances	15,227
Write-off of provision for receivables overdue for more than 02 years	6,810
Balance at March 31, 2013	<u>(107,718)</u>

10. Inventories

	<u>Company</u>		<u>Consolidated</u>	
	<u>03/31/13</u>	<u>12/31/12</u>	<u>03/31/13</u>	<u>12/31/12</u>
Direct domestic material	17,733	18,265	29,775	32,523
Imported direct material	5,422	7,301	8,256	11,399
Domestic secondary material	7,842	9,661	10,135	12,211
Consumption material	3,993	4,483	5,202	5,854
Provision for obsolescence	(250)	(250)	(257)	(545)
	<u>34,740</u>	<u>39,460</u>	<u>53,111</u>	<u>61,442</u>

Notes to the quarterly information**11. Taxes recoverable**

	Company		Consolidated	
	03/31/13	12/31/12	03/31/13	12/31/12
INSS recoverable	3,926	3,442	24,588	23,794
Withholding income tax	6,212	1,712	9,335	1,520
Income tax recoverable	12,421	24,028	29,447	39,044
Social contribution tax recoverable	26,493	23,052	35,886	30,192
COFINS and PIS withheld	19,842	18,916	26,757	25,354
Withheld service tax (ISS)	4,740	5,213	12,374	12,440
Other	5,807	5,679	6,246	6,118
	79,441	82,042	144,633	138,462

12. Investmentsa) Information on investments in subsidiaries

	Company		Consolidated	
	03/31/13	12/31/12	03/31/13	12/31/12
DASA Real Estate Empreendimentos Imobiliários Ltda.	31,257	30,969		
CientíficaLab Produtos Laboratoriais e Sistemas Ltda	90,536	83,019	-	-
Instituto de Endocrinologia e Medicina Nuclear do Recife S.A. (CERPE)	31,656	29,370	-	-
CDPI - Clínica de Diagnóstico por Imagem Ltda.	35,491	38,459	-	-
CRMI - Clínica de Ressonância e Multi Imagem Ltda.	11,356	10,768	-	-
Pro Echo Cardiodata Serviços Médicos Ltda.	86,906	83,914	-	-
Laboratórios Médicos Dr. Sérgio Franco Ltda.	119,671	101,820	-	-
Previlab - Análises Clínicas Ltda.	23,517	23,035	-	-
Dasa Property Participações Ltda.	50	50	-	-
Dasa Nordeste Participações Ltda	50	50	-	-
Dasa Centro Oeste Participações Ltda.	50	50	-	-
Dasa Sudoeste Participações Ltda.	50	50	-	-
	430,590	401,554	-	-
Other investments	624	361	873	516
	431,214	401,915	873	516

Notes to the quarterly information

Subsidiaries	Base date	Number of shares or quotas	Number of shares or quotas held (thousand)	Percentage of interest in capital	Paid-in capital	Equity (capital deficiency)	Income (loss) for the period
DASA Real Estate	03/31/2013	25,667,079	25,667,078	99.99	25,667	31,257	288
	12/31/2012	25,667,079	25,667,078	99.99	25,667	30,969	9,170
CientíficaLab	03/31/2013	49,676,629	49,676,628	99.99	49,677	90,536	(3,983)
	12/31/2012	27,176,629	27,176,628	99.99	38,177	83,019	(13,588)
DASA Finance (i)	03/31/2013	50,000	50,000	100.00	80	(27,343)	(1,214)
	12/31/2012	50,000	50,000	100.00	80	(26,130)	(4,219)
CERPE	03/31/2013	122,024	120,804	99.00	122	31,656	2,286
	12/31/2012	122,024	120,804	99.00	122	29,370	(2,467)
CDPI	03/31/2013	1,834,280	1,834,279	99.99	18,343	35,491	(2,968)
	12/31/2012	1,834,280	1,834,279	99.99	18,343	38,459	7,391
CRMI	03/31/2013	2,508,000	2,507,999	99.99	2,508	11,356	588
	12/31/2012	2,508,000	2,507,999	99.99	2,508	10,768	2,556
Pro Echo	03/31/2013	131,483,058	91,483,058	69.58	131,483	124,722	2,992
	12/31/2012	131,483,058	91,483,058	69.58	131,483	120,428	179
Lab. Méd. Dr. Sérgio Franco	03/31/2013	63,902,082	63,902,081	99.99	63,902	119,671	17,852
	12/31/2012	63,902,082	63,902,081	99.99	63,902	101,820	71,257
Previlab	03/31/2013	23,113,314	23,009,743	99.56	23,113	23,517	481
	12/31/2012	23,113,314	23,009,743	99.56	21,198	23,035	-
Dasa Property Part.	03/31/2013	50,000	49,500	99.00	50	50	-
	12/31/2012	50,000	49,500	99.00	50	50	-
Dasa Nordeste Part.	03/31/2013	50,000	49,500	99.00	50	50	-
	12/31/2012	50,000	49,500	99.00	50	50	-
Dasa Centro Oeste Part.	03/31/2013	50,000	49,500	99.00	50	50	-
	12/31/2012	50,000	49,500	99.00	50	50	-
Dasa Sudoeste Part.	03/31/2013	50,000	49,500	99.00	50	50	-
	12/31/2012	50,000	49,500	99.00	50	50	-

(i) Investment in DASA Finance is classified in current liabilities of the Company for presenting negative equity.

Notes to the quarterly informationb) Changes in investments

	Balances at 12/31/12	Capital increase	Equity pickup	Balances at 03/31/13
DASA Real Estate	30,969	-	288	31,257
CientíficaLab	83,019	11,500	(3,983)	90,536
CERPE	29,370	-	2,286	31,656
CDPI	38,459	-	(2,968)	35,491
CRMI	10,768	-	588	11,356
Pro Echo	83,914	-	2,992	86,906
Lab. Méd. Dr. Sérgio Franco	101,820	-	17,851	119,671
Previlab	23,035	-	482	23,517
Dasa Property Part.	50	-	-	50
Dasa Nordeste Part.	50	-	-	50
Dasa Centro Oeste Part.	50	-	-	50
Dasa Sudoeste Part.	50	-	-	50
	401,554	11,500	17,536	430,590
Negative equity			(1,214)	
			16,322	

13. Property and equipment

	Average depreciation rate % p.a.	Company			12/31/12
		03/31/13		Net	
		Cost	Accumulated depreciation		
Buildings	4.00	824	(519)	305	312
Leasehold improvements	7.80	381,746	(230,642)	151,104	145,515
Machinery and equipment	7.05	338,929	(94,408)	244,521	252,109
Furniture and fixtures	10.12	40,403	(13,280)	27,123	27,518
Facilities	8.37	33,276	(9,657)	23,619	20,726
IT equipment	10.69	112,172	(48,034)	64,138	60,354
Vehicles	19.17	3,780	(3,272)	508	594
Library	7.48	147	(118)	29	32
Land	-	180	-	180	180
Construction in progress	-	27,112	-	27,112	32,468
		938,569	(399,930)	538,639	539,808

Notes to the quarterly information

	Average depreciation rate % p.a.	Consolidated			
		03/31/13			12/31/12
		Cost	Accumulated depreciation	Net	Net
Buildings	4.00	4,564	(1,480)	3,084	3,128
Leasehold improvements	8.14	464,119	(261,540)	202,579	198,178
Machinery and equipment	6.17	449,818	(136,044)	313,774	319,432
Furniture and fixtures	9.21	55,797	(16,289)	39,508	40,224
Facilities	11.52	54,576	(19,468)	35,108	31,877
IT equipment	11.24	114,730	(46,178)	68,552	65,132
Vehicles	19.55	5,682	(4,981)	701	839
Library	5.15	233	(196)	37	41
Land	-	6,574	-	6,574	6,574
Construction in progress		41,015	-	41,015	51,049
		1,197,108	(486,176)	710,932	716,474

Changes in cost

	Company				
	Changes for the period				
	12/31/12 Adjusted (a)	Additions	Write off	Transf.	03/31/13
Buildings	824	-	-	-	824
Leasehold improvements	370,096	6,789	-	4,861	381,746
Machinery and equipment	335,624	5,845	(2,896)	356	338,929
Furniture and fixtures	39,211	1,192	-	-	40,403
Facilities	29,617	2,867	-	792	33,276
IT equipment	103,448	7,354	-	1,370	112,172
Vehicles	3,822	-	(42)	-	3,780
Library	147	-	-	-	147
Land	180	-	-	-	180
Construction in progress	32,468	3,541	-	(8,897)	27,112
	915,437	27,588	(2,938)	(1,518)	938,569

Notes to the quarterly information

	Consolidated				03/31/13
	Changes for the period				
	12/31/12 Adjusted (a)	Additions	Write off	Transf.	
Buildings	4,564	-	-	-	4,564
Leasehold improvements	451,728	7,151	-	5,240	464,119
Machinery and equipment	440,573	6,930	(2,589)	4,904	449,818
Furniture and fixtures	54,459	1,350	(12)	-	55,797
Facilities	50,143	3,642	(1)	792	54,576
IT equipment	105,857	7,461	-	1,412	114,730
Vehicles	5,954	-	(272)	-	5,682
Library	233	-	-	-	233
Land	6,574	-	-	-	6,574
Construction in progress	51,049	3,541	-	(13,575)	41,015
	1,171,134	30,075	(2,874)	(1,227)	1,197,108

- (a) For better presentation, the accumulated depreciation of certain assets items was offset with their respective cost in order to reflect their deemed cost adopted upon implementation of IFRS and CPC standards.

Changes in accumulated depreciation

	Company			03/31/13
	Changes for the period			
	12/31/12 Adjusted (a)	Additions	Write off	
Buildings	(512)	(7)	-	(519)
Leasehold improvements	(224,581)	(6,061)	-	(230,642)
Machinery and equipment	(83,515)	(12,056)	1,163	(94,408)
Furniture and fixtures	(11,693)	(1,587)	-	(13,280)
Facilities	(8,891)	(766)	-	(9,657)
IT equipment	(43,094)	(4,940)	-	(48,034)
Vehicles	(3,228)	(81)	37	(3,272)
Library	(115)	(3)	-	(118)
	(375,629)	(25,501)	1,200	(399,930)

	Consolidated			03/31/13
	Changes for the period			
	12/31/12 Adjusted (a)	Additions	Write off	
Buildings	(1,436)	(44)	-	(1,480)
Leasehold improvements	(253,550)	(7,990)	-	(261,540)
Machinery and equipment	(121,141)	(15,829)	926	(136,044)
Furniture and fixtures	(14,235)	(2,063)	9	(16,289)
Facilities	(18,266)	(1,202)	-	(19,468)
IT equipment	(40,725)	(5,453)	-	(46,178)
Vehicles	(5,115)	(131)	265	(4,981)
Library	(192)	(4)	-	(196)
	(454,660)	(32,716)	1,200	(486,176)

Notes to the quarterly information

- (a) For better presentation, the accumulated depreciation of certain assets items was offset with their respective cost in order to reflect their deemed cost upon implementation of IFRS and CPC standards.

Additions to accumulated depreciation, stated in changes for the period, were partly recorded under general and administrative expenses and partly under costs of goods and/or services sold.

14. Intangible assets

	Average depreciation rate % p.a.	Company					
		03/31/13			12/31/12		
		Cost	Accumulated amortization		Cost	Accumulated amortization	
Interest acquisition - Goodwill		2,128,232	(153,831)	1,974,401	2,128,232	(153,831)	1,974,401
Other intangible							
IT systems	20	153,681	(90,716)	62,965	142,380	(85,444)	56,936
Right of use of commercial area	20	1,203	(573)	630	1,203	(537)	666
Other intangible assets	20	12,628	(4,051)	8,577	12,628	(3,622)	9,006
Systems implementation project	20	12,293	(12,293)	-	12,293	(12,293)	-
Project development	33	10,259	(10,259)	-	10,259	(10,166)	93
Trademarks	3.3	236,037	(17,218)	218,819	236,037	(15,300)	220,737
Exclusive agreement with customers - Unimagem	10	9,403	(4,001)	5,402	9,403	(3,767)	5,636
Agreements with hospitals	5	35,748	(4,641)	31,107	35,748	(4,188)	31,560
		471,252	(143,752)	327,500	459,951	(135,317)	324,634
		2,599,484	(297,583)	2,301,901	2,588,183	(289,148)	2,299,035
Consolidated							
	Average amortization rate % p.a.	03/31/13			12/31/12		
		Cost	Accumulated amortization	Net	Cost	Accumulated amortization	Net
Interest acquisition - Goodwill		2,206,183	(205,309)	2,000,874	2,206,183	(205,309)	2,000,874
Other intangible							
IT systems	20	159,419	(93,778)	65,641	147,885	(88,254)	59,631
Right of use of commercial area	20	1,359	(648)	711	1,359	(612)	747
Other intangible assets	20	14,018	(4,073)	9,945	14,018	(3,634)	10,384
Systems implementation project	20	12,293	(12,293)	-	12,293	(12,293)	-
Project development	33	10,267	(10,267)	-	10,267	(10,210)	57
Trademarks	3.3	251,663	(18,603)	233,060	251,663	(16,441)	235,222
Exclusive agreement with customers - Unimagem	10	9,403	(4,002)	5,401	9,403	(3,767)	5,636
Agreements with hospitals	5	40,488	(6,238)	34,250	40,488	(5,597)	34,891
		498,910	(149,902)	349,008	487,376	(140,808)	346,568
		2,705,093	(355,211)	2,349,882	2,693,559	(346,117)	2,347,442

Notes to the quarterly informationChanges in cost

	Company			03/31/13
	Changes for the period			
	12/31/12	Additions	Transfers	
Interest acquisition - Goodwill	2,128,232	-	-	2,128,232
Other intangible				
IT systems	142,380	11,131	170	153,681
Right of use of commercial area	1,203	-	-	1,203
Other intangible assets	12,628	-	-	12,628
Systems implementation project	12,293	-	-	12,293
Project development	10,259	-	-	10,259
Trademarks	236,037	-	-	236,037
Exclusive agreement with customers – Unimagem	9,403	-	-	9,403
Agreements with hospitals	35,748	-	-	35,748
	459,951	11,131	170	471,252
	2,588,183	11,131	170	2,599,484

	Consolidated			03/31/13
	Changes for the period			
	12/31/12	Additions	Transfers	
Interest acquisition - Goodwill	2,206,183	-	-	2,206,183
Other intangible				
IT systems	147,885	11,201	333	159,419
Right of use of commercial area	1,359	-	-	1,359
Other intangible assets	14,018	-	-	14,018
Systems implementation project	12,293	-	-	12,293
Project development	10,267	-	-	10,267
Trademarks	251,663	-	-	251,663
Exclusive agreement with customers - Unimagem	9,403	-	-	9,403
Agreements with hospitals	40,488	-	-	40,488
	487,376	11,201	333	498,910
	2,693,559	11,201	333	2,705,093

Notes to the quarterly informationChanges in accumulated amortization

	Company		
	Changes for the period		
	12/31/12	Amortization	03/31/13
Interest acquisition - Goodwill	(153,831)	-	(153,831)
Other intangible			
IT systems	(85,444)	(5,272)	(90,716)
Right of use of commercial area	(537)	(36)	(573)
Other intangible assets	(3,622)	(429)	(4,051)
Systems implementation project	(12,293)	-	(12,293)
Project development	(10,166)	(93)	(10,259)
Trademarks	(15,300)	(1,918)	(17,218)
Exclusive agreement with customers - Unimagem	(3,767)	(234)	(4,001)
Agreements with hospitals	(4,188)	(453)	(4,641)
	(135,317)	(8,435)	(143,752)
	(289,148)	(8,435)	(297,583)
	Consolidated		
	Changes for the period		
	12/31/12	Amortization	03/31/13
Interest acquisition - Goodwill	(205,309)	-	(205,309)
Other intangible			
IT systems	(88,254)	(5,524)	(93,778)
Right of use of commercial area	(612)	(36)	(648)
Other intangible assets	(3,634)	(439)	(4,073)
Systems implementation project	(12,293)	-	(12,293)
Project development	(10,210)	(57)	(10,267)
Trademarks	(16,441)	(2,162)	(18,603)
Exclusive agreement with customers - Unimagem	(3,767)	(235)	(4,002)
Agreements with hospitals	(5,597)	(641)	(6,238)
	(140,808)	(9,094)	(149,902)
	(346,117)	(9,094)	(355,211)

Additions to accumulated amortization, stated in changes for the period, were partly recorded under general and administrative expenses and partly under costs of goods and/or services sold.

Notes to the quarterly information**15. Trade accounts payable**

	Company		Consolidated	
	03/31/13	12/31/12	03/31/13	12/31/12
Domestic suppliers	51,171	53,460	80,519	83,138
Foreign suppliers	349	1,254	390	1,291
	51,520	54,714	80,909	84,429

16. Loans and financing

Modality	Average charges	Final maturity	Company		Consolidated	
			03/31/13	12/31/12	03/31/13	12/31/12
Local currency						
Banco HSBC	113.0% of CDI	03/25/2013	-	1,251	-	1,251
Banco do Brasil (iii)	111.0% of CDI	06/01/2015	-	-	25,789	28,669
BNDES (ii) and (iii)	TJLP + 5.8% p.a.	05/15/2016	-	-	-	3,117
Other banks	115.0% of CDI	11/29/2012	-	-	17	70
Leasing – Other banks - Note 27 (i), (ii) and (iii)	CDI + 4.0% p.a.	10/26/2015	7,292	8,246	24,868	30,801
			7,292	9,497	50,674	63,908
Foreign currency						
Equipment financing (i), (ii) and (iii)	7.10% p.a.	12/01/2016	-	-	3,666	3,862
Leasing – Other banks - Note 27 (ii) and (iii)	6.69% p.a.	03/23/2016	14,298	18,655	16,729	21,387
Notes (<i>Senior Notes</i>) (a) (iii)	8.75% p.a.	05/29/2018	-	-	60,055	59,652
			14,298	18,655	80,450	84,901
Transaction cost – issue of notes (c)			-	-	(1,328)	(1,412)
			21,590	28,152	129,796	147,397
Current liabilities			(13,683)	(16,840)	(38,794)	(44,520)
Non-current liabilities			7,907	11,312	91,002	102,877

The Company is not exposed to short-term refinancing risk.

Guarantors:

- (i) DASA Real Estate Empreendimentos Imobiliários Ltda.
- (ii) Promissory Note of 125% of contractual amount in the Company's name.
- (iii) Diagnósticos da América S.A.

Notes to the quarterly information

Bank loan and financing agreements do not have covenants.

- (a) The Board of Directors, in a meeting held on May 21, 2008, approved the issue of notes (*Senior Notes*) by the foreign subsidiary, DASA Finance Corporation, for the purpose of raising funds to finance the Company's activities expansion. The issuance of notes in the amount of US\$ 250 million was completed on May 29, 2008, with maturity in a lump-sum in May 2018, remunerated at an interest rate of 9.45% p.a. The interest is paid on a semiannual basis, on May 29 and November 29 of each year. Both principal amount and interest are guaranteed unconditionally and irrevocably by the Company. The notes were placed exclusively abroad. The balance at March 31, 2013 is R\$60,055 (R\$59,652 at December 31, 2012).
- (b) The transaction costs will be allocated to profit or loss on a straight-line basis, until the settlement of the notes, subject to adjustment in the effective rate of the loan

Bank loans and financing classified as non-current liabilities, according to the contractual maturity dates, will be repaid as follows:

	<u>Company</u>	<u>Consolidated</u>
2014 (as from April 1)	5,468	21,799
2015	2,375	11,448
2016 to 2018	64	58,826
Transaction cost - long term	-	(1,071)
	<u>7,907</u>	<u>91,002</u>

The Company granted collaterals to its subsidiaries as follows:

CDPI - Clínica de Diagnóstico por Imagem Ltda.	Banco ABC Brasil	4,521
	General Eletric	620
	Banco Itaú S.A.	2,478
	Banco do Brasil	5,000
CientificaLab Produtos Lab. e Sistemas Ltda.	CSI Latina Financial	272
	Modal	48
	Banco Pottencial	2,429
DASA Finance Corporation	Emissão de Bond	58,362
Laboratórios Médicos Dr.Sérgio Franco Ltda.	Banco Itaú S.A.	2,712
	Banco do Brasil	25,000
	Banco Pottencial	10
Pro Echo Cardiodata Serviços Médicos Ltda.	General Eletric	639
	Banco Itaú S.A.	1,099
CRMI - Clínica de Ressonância e Multi Imagem Ltda.	Banco do Brasil	4,000
		<u>107,190</u>

Notes to the quarterly information**17. Debentures (Company and consolidated)**

	<u>03/31/13</u>	<u>12/31/12</u>
Non-convertible debentures	950,000	950,000
Remuneration Interest	31,670	13,239
	981,670	963,239
Transaction cost	(3,941)	(4,255)
	977,729	958,984
Current	(92,917)	(74,485)
Non-current	884,812	884,499

Deadline for amortization of the main value of second- and third-issue debentures is as follows:

2013	62,500
2014	295,833
2015	295,833
2016	295,834
	<u>950,000</u>

2nd Issue

In the meeting held on March 16, 2011, the Board of Directors of the Company approved a fund raising by conducting the 2nd issue of simple debentures not convertible into shares of the Company, for public distribution in the total amount of up to R\$810,000, on a firm guarantee and better efforts of placement basis, under the terms of CVM Ruling No. 476 of January 16, 2009.

On May 16, 2011, the Company informed its shareholders and the market in general that, on May 11, 2011, it closed the public offer for distribution with restricted placement efforts, of a single series of simple debentures non-convertible into shares, of the unsecured type. Seventy thousand (70,000) Debentures were subscribed, with a five (5) year term from the date of issue, therefore due on April 29, 2016, in the total amount of R\$700,000. The Debentures account for remuneration equivalent to one hundred percent (100%) of accumulated variation of the daily average rates of the DI – Interbank Deposits of one day, over extra-group, expressed as a percentage per year, based on a year of two hundred and fifty-two (252) working days, calculated and daily published by CETIP, plus an exponential surcharge corresponding to one point forty percent (1.40%) per year. As the issue date was April 29, 2011, the face value of each debenture will be paid in 3 consecutive yearly installments, from the 36th (thirty sixth) month as from issue date. Payment of remuneration interest is semiannual, occurring on the 1st day of April and October, and the debit in the Company account shall occur one day prior to the due date.

Notes to the quarterly information

The transaction cost will be realized up to April 2016, totaling R\$3,941 at the date of the transaction.

3rd Issue

On October 15, 2012, the Board of Directors of the Company approved the third issue by the Company, of up to 25,000 debentures non-convertible into shares of the unsecured type, in a single series, in the total amount of up to R\$250,000, for placement through a public offer with restricted efforts, pursuant to CVM Instruction No. 476 of January 16, 2009, as amended.

On November 1, 2012 the Company informed its shareholders and the market in general that, on October 31, 2012, it closed the public offer for distribution with restricted placement efforts, of the third issue of DASA's simple debentures, non-convertible into shares, of the unsecured type, in one single series. Twenty five thousand (25,000) Debentures were subscribed, with a four (4) year term from the date of issue, in the total amount of R\$250,000. The Debentures shall not be subject to adjustment for inflation, and the outstanding amount of the face value of each Debenture account for remuneration equivalent to one hundred percent (100%) of accumulated variation of the daily average rates of the DI – Interbank Deposits of one day, over extra-group, expressed as a percentage per year, based on a year of two hundred and fifty-two (252) working days, calculated and daily published by CETIP, plus a surcharge corresponding to zero point eighty per cent (0.80%) per year, based on a year of two hundred and fifty-two (252) working days, calculated on an exponential and cumulative *pro rata temporaris* basis by working day elapsed from the Issue Date, or the immediate previous interest payment date, as the case may be, until the actual date of payment.

Interest will be paid semiannually from the Issue Date, the first payment beginning on April 25, 2013 and the last payment to be made on the Maturity Date, without prejudice to payments resulting from early redemption of the Debentures, early repayment of the Debentures and/or prepayment of obligations arising out of the Debentures.

The face value of each Debenture will be repaid in 4 annual and successive installments, in the following order:

- I. Three installments, each in the amount corresponding to 25% of the face value of each Debenture, due on October 25, 2013, October 25, 2014 and October 25, 2015; and
- II. One installment in the amount corresponding to the outstanding balance of the face value of each Debenture, due on October 25, 2016.

The financial settlement of the offer occurred on October 31, 2012 in the amount of R\$250,304, and the net proceeds of the offer were used towards (i) the early redemption of all commercial promissory notes of the third issue of the Company; and (ii) the balance to reinforce the working capital of the Company.

The debentures have clauses establishing maximum indebtedness and leverage ratios, based on the consolidated Quarterly information, according to Note 25. At the closing of the period, the Company was in compliance with the contractual covenants as follows:

Notes to the quarterly information

Ratio	Contractual condition (a)	Ratio on 03/31/2013	Ratio on 12/31/2012
1 - Net Debt/EBITDA - maximum ratio			
2nd Issue	2.50	2.21	2.08
3rd Issue	3.00	2.21	2.08
2 - EBITDA/Financial Income - minimum ratio			
2nd Issue	2.00	3.76	3.58
3rd Issue	2.00	3.76	3.58

(a) The Company will be deemed to be in non-compliance with this covenant if it exceeds such ratios for two consecutive quarters.

18. Social and labor liabilities

	Company		Consolidated	
	03/31/13	12/31/12	03/31/13	12/31/12
Salaries payable	11,414	11,905	15,213	16,598
Social charges payable	9,586	10,963	13,065	14,991
Provision for vacation and social charges	40,924	36,184	55,252	48,366
Provision for profit sharing	7,500	-	7,500	-
Other	1,723	357	2,262	1,236
	71,147	59,409	93,292	81,191

19. Taxes in installments

	End of amortization	Company		Consolidated	
		03/31/13	12/31/12	03/31/13	12/31/12
PAES program (a)	2013	3,487	1,155	3,487	1,155
REFIS IV – Federal (b)	2020	9,977	10,113	20,289	21,208
ICMS – RJ (c)		-	-	3,500	5,103
Other		1,045	1,124	4,962	5,364
		14,509	12,392	32,238	32,830
Current		(4,797)	(2,370)	(6,349)	(4,820)
Non-current		9,712	10,022	25,889	28,010

(a) On July 29, 2003, the Company enrolled with the Tax Payment in Installments Plan (Program PAES) (Law No. 10.684), declaring tax debts related to PIS and COFINS which were being discussed in court. The total amount of debt is divided into 120 monthly installments and adjusted using the long-term interest rate (TJLP). Payment of these installments extends to June 2013, and the Company does not make any payment based on gross revenue, has not used, nor shall use tax credits to amortize fines and interest. In March 2013, the Company recorded a supplementary amount of R\$ 2,767, in order to reflect the balance payable in the existing PAES, in the statement provided by the Brazilian IRS. Of this amount, R\$ 1,743 were recorded under General and administrative expenses, and refer to (i) debts for years 1998 to 2001 for entities acquired by the Company (Bronstein, Lâmina and Lavoisier), and (ii) late payment fine, applied to PIS (payable by the Company) and COFINS (payable by the acquired entity Lâmina) taxes, decreased by 50%, the legal enforceability of which was previously challenged by the Company. The remaining amount of R\$ 1,024 was recorded under Financial expenses and refers to interest adjusted according to the long-term interest rate (TJLP) applied to such debts, consolidated by the Company in March 2013. At March 31, 2013, the Company and consolidated balance is R\$ 3,487 (R\$ 1,115 at December 31, 2012).

Notes to the quarterly information

(b) Special federal tax installment program - Law 11.941/09 (REFIS IV)

With the enactment of Law No. 11.941/09, a new special installment program (REFIS IV) was established comprising all debts under the Brazilian Federal Tax Authorities (Brazilian IRS, National Finance Attorney General Office - PGFN and Brazilian Institute of Social Security – INSS), whether or not incurred or registered as Federal Executable Tax Debt, even if an execution order has already been filed, including those subject to a previous installment program. Given the favorable conditions of this new Program, the Company enrolled therewith on November 27, 2009, and made the first installment payment under the conditions provided for in law, monthly paying the minimum installments until the actual consolidation of the debt. The Company balance at March 31, 2013 is R\$9,977 (R\$10.113 on December 31, 2012) and the consolidated balance at March 31, 2013 is R\$20.289 (R\$21,208 on December 31, 2012).

The Company also included in the installment program tax debts for which former partners/shareholders of the acquired companies were liable. Such debts have not been recorded under taxes in installments yet, because the review process with the former owners has not been concluded. This process should result in the redemption, proportional to the debts assumed by the prior management, of marketable securities used as guarantees for settlement of liabilities assumed at the time the companies were acquired (Note 8).

The term for consolidation of debts in the special installment plan for major taxpayers with differentiated monitoring ended on June 30, 2011. The Company has not concluded the consolidation yet, as information about debts originated from the companies acquired by the Company, which have already been merged, was not available on the Brazilian IRS website during the period of consolidation. The Company, aiming to ensure recognition of the acquired companies debts in the installment program, has filed for petitions in the period between June 27 and 28, 2011 before the agencies handling debts subject to the installment plan, requiring such debts to be stated as entitled to inclusion in the installment payment on the E-CAC system. The Company has not yet received an answer to petitions filed.

(c) ICMS – RJ Payment in installments

Special tax debt payment in installments in Rio de Janeiro – Law 6.136/11

Rio de Janeiro State Law No. 6136/11, regulated by Rio de Janeiro State Decree No. 43443/12 and Resolution No. 3080/12 of Rio de Janeiro State General Prosecution Office, enacted a special program that provides for elimination of 100% of fines and 50% of interest on debts registered as Enforceable Tax Debt, authorizing payment thereof within 18 months or through offset against securities issued in connection with court ordered debts (“precatórios”), observing the limit of 95% of debts.

Considering these favorable conditions, the Company, through its subsidiaries Clínica de Ressonância e Multi-Imagem Ltda. (CRMI), Pro Echo Cardiodata Serviços Médicos Ltda. (Pro Echo) e CDPI – Clínica de Diagnóstico por Imagem Ltda. (CDPI), elected to use the benefits of Law, adhering to the program on 05/31/2012 and thus eliminating the tax contingencies related to ICMS on import recorded in provision accounts (Note 21).

The subsidiaries adhered to pay the debts through offset against securities issued in connection with court ordered debts, subject to the limits provided for in the law, and CDPI also elected to settle part of its debts in 18 monthly installments.

On June 1, 2012, there was full payment of lawyers' fees related to debts in relation to which the Company opted for offset against securities issued in connection with court ordered debts, in accordance with article 34 Resolution No. 3080/12 of the Rio de Janeiro State General Prosecution Office. On the same date, there was payment of the first installment of debts payable in 18 monthly installments.

The modality of offset against securities issued in connection with court ordered debts depends on approval by the Chief of Staff and, upon such approval, there shall be payment in cash of 5% of waived debts that may not be offset against such securities, after summons by PGE (the State General Prosecution Office), under penalty of offset to be considered invalid on the terms of article 10 of Law No. 6.136/11. Only upon approval, will the Company recognize in P&L the discount on the acquisition of the securities used to offset the debts.

Notes to the quarterly information

The total amount of debts included in said Special Installment Plan, as well as the breakdown of its settlement – offsetting with court ordered debts or payment in kind - is as follows:

	Total	Court Ordered Debt s	In Cash
Clínica de Ressonância e Multi-Imagem Ltda.	3,197	2,944	253
Pro Echo Cardiodata Serviços Médicos Ltda.	784	725	59
CDPI – Clínica de Diagnóstico por Imagem Ltda.	10,639	9,813	816
	<u>14,610</u>	<u>13,482</u>	<u>1,128</u>

The breakdown of discount accruing on the acquisition of court ordered debts, in turn, is as follows:

	Nominal value	Discount	Amount paid
Clínica de Ressonância e Multi-Imagem Ltda.	2,945	(960)	1,985
Pro Echo Cardiodata Serviços Médicos Ltda.	725	(227)	498
CDPI – Clínica de Diagnóstico por Imagem Ltda.	9,813	(3,243)	6,570
	<u>13,483</u>	<u>(4,430)</u>	<u>9,053</u>

The nominal value of negative goodwill securities issued to cover court-ordered debts at March 31, 2013 is R\$ 1,985, and was registered under Other non-current assets.

On December 27, 2012, the State Official Gazette of Rio de Janeiro (DOERJ) published an order of the Chief of Staff, ratifying granting of administrative proceeding E14-515,131/2012, corresponding to one (1) of the two (2) offsets claimed, as filed by CDPI. Accordingly, such offsetting has been already accounted for by write off of both the ICMS debits reported in the offsetting request, as well as the court ordered debts used, totaling R\$9,562. Furthermore, the portion of discount relating to such court ordered debts offset in the amount of R\$3,160 was also recognized under financial income. Payment in the amount of 5% of debts waived, not subject to offsetting against court ordered debts, was made on March 27, 2013 after due summons by PGE (State Attorney General's Office). The approval of the administrative proceeding E-14-515.132/2012 was recognized in this period, and its nominal value corresponds to R\$251 with a discount of R\$83, recorded under Financial expenses.

DOERJ also published on January 8, 2013 an order granting offsets claimed by the Company PRO ECHO, so that the accounting for both offset and recognition of the portion of discount in the statement of income were made in this period. Total securities issued to cover court-ordered debts offset amounted to R\$ 725, with negative goodwill of R\$ 227, recognized under Financial income.

The balance of ICMS paid installments as of March 31, 2013 is R\$ 3,500 (R\$ 5,103 at December 31, 2012) for the consolidated.

20. Accounts payable for acquisitions of subsidiaries

Accounts payable for acquisition of subsidiaries relate to the amounts due to their former owners upon the acquisition of shares or quotas representing the paid-in capital of these companies. Debts are restated in accordance with contractual clauses and have the following settlement schedules:

Notes to the quarterly information

	Restatement	Maturity	Company		Consolidated	
			03/31/13	12/31/12	03/31/13	12/31/12
Not guaranteed by financial investments	IPCA-IGPM-Selic	05/2016	10,645	11,797	10,646	11,797
Guaranteed by financial investments	(a)	11/2016 and 04/2017	46,849	46,803	57,859	57,635
			57,494	58,600	68,505	69,432
Current			(1,618)	(1,598)	(1,618)	(1,598)
Non-current			55,876	57,002	66,887	67,834

(a) Restated at the average Interbank Deposit Certificate (CDI) rate of 103.39% (102.63% of CDI rate at December 31, 2012) in fixed income funds, and 100.00% of CDI (100.00% of CDI rate at December 31, 2012) in Bank Deposit Certificates (CDB) / committed transactions, which are administered by financial institutions, as presented in Note 8.

The installments classified as non-current liabilities have the following payment schedule:

Year of maturity	Company	Consolidated
2014 (as from April 1)	14,697	14,697
2015	15,223	15,223
2016	25,841	32,839
2017 to 2020	115	4,128
Total	55,876	66,887

21. Provisions for tax, social security, labor and civil proceedings

	Company			
	03/31/2013		12/31/2012	
	Provision	Judicial Deposit	Provision	Judicial Deposit
ICMS on import (a)	97,011	51,782	96,155	51,642
Civil and labor contingencies (b)	5,337	9,994	4,182	9,908
Tax contingencies (c)	28,542	29,814	28,589	29,567
	130,890	91,590	128,926	91,117

	Consolidated			
	03/31/2013		12/31/2012	
	Provision	Judicial Deposit	Provision	Judicial Deposit
ICMS on import (a)	97,011	51,782	96,155	51,642
Civil and labor contingencies (b)	6,187	10,066	5,057	9,980
Tax contingencies (c)	30,992	33,887	31,039	33,652
	134,190	95,735	132,251	95,274

Notes to the quarterly information

(a) ICMS on import

The Company, based on the opinion of its legal advisors, has not paid ICMS on the import of inputs and equipment for use in the rendering of its services, since February 2000, as there are ongoing discussions as to whether the Company is an ICMS taxpayer for these transactions. For ICMS payable on goods and equipment imported up to the publication of Constitutional Amendment 33 on December 11, 2001, the outside legal advisors understand that the likelihood of losses is remote; as regards amounts of ICMS payable generated in the period between Constitutional Amendment 33 and the issuance of Supplementary Law No. 114, on December 16, 2002, the likelihood of loss was rated as possible. Finally, after the issuance of Supplementary Law No. 114 on December 16, 2002, the outside legal advisors understand that the likelihood of loss is probable. Accordingly, the Company decided to deposit in court, in December 2011, the amount of R\$46,068 regarding ICMS amounts on non-assessed direct import of inputs and equipment cleared in the State of São Paulo totaling R\$46,068, claiming the right to settle the tax by voluntary payment without fines and with reduced interest, the criteria for calculating the provision for losses being maintained. The lower court deemed the claim to be partially valid for the Company regarding arguments submitted for collection of interest and invalid regarding the fine. The decision is subject to appeal.

At March 31, 2013, the provision recorded for imports made as from January 1, 2003 is R\$97,011 (R\$96,155 at December 31, 2012) for the Company and Consolidated statements, with judicial deposits amounting to R\$51,781 (R\$51,642 at December 31, 2012).

(b) Provisions for labor and civil risks:

At March 31, 2013, the Company is a party to 948 labor claims (916 at December 31, 2012) and 893 civil administrative proceedings and lawsuits (897 at December 31, 2012). Provisions in the amount of R\$5,337 (R\$4,182 at December 31, 2012) for the Company and R\$6,187 (R\$5,057 at December 31, 2012) in the consolidated statements are based on the historical percentage of loss of claims whose likelihood of an unfavorable outcome has been rated as probable. Still at March 31, 2013, the Company recorded the consolidated amount of R\$ 73,837 (R\$ 78,570 at December 31, 2012) related to the claims classified by its legal advisors as possible loss, from which R\$18,295 refers to civil claims and R\$ 55,542 to labor claims for which there are no provisions, according to the accounting rule applicable for those circumstances.

The Company is also a party to a lawsuit for indemnification for loss of profits and pain and suffering due to supposed competition infraction by the Company together with a health insurance Company, intended to remove it from the market. An opposition and challenge was filed against the case amount, against which claimants filed a reply. and an expert accounting and engineering examination was ordered. The amount attributed to the case by claimant is R\$ 61,815 on December 7, 2007, which unfavorable outcome was classified as possible, and the amount involved has not been evaluated. Forensic accounting was carried out by the court expert concluding that the loss of profits sought would be R\$4,500.

The Company and its subsidiary Laboratórios Médicos Dr. Sérgio Franco Ltda. were summoned in a Public Civil Action in course at the Labor Court of Rio de Janeiro, which, generally speaking, questions the legality of employing specialist medical companies in the area of diagnostic imaging support exams, requiring the hiring of physicians subject to the Consolidation of Labor Laws and compensation for collective pain and suffering in an approximate amount of R\$ 20,000 on September 10, 2012. The Company believes that, by its specific features, the form of contract it has been adopting, in addition to being in regular and in strict compliance with applicable legal provisions, has previous case law favorable support, in line with what it has disclosed and explained in the Reference Form in items 4.1 and 4.3. On October 29, 2012, the Company disclosed such summons as a "Material Fact", in compliance with CVM Instruction No. 358 of January 2002. A hearing was held on February 20, 2013, which was postponed *sine die*. Management of their legal advisors evaluation is that the chance of loss is possible.

(c) Provisions for tax contingencies

Provisions for tax contingencies amounting to R\$28,542 at March 31, 2013 for the Company (R\$28,589 at December 31, 2012) and R\$30,992 at March 31, 2013 in the consolidated statements (R\$31,039 at December 31, 2012) corresponding to (i) questions regarding increase in tax rates, (ii) basis of calculation, and (iii) the unconstitutionality of the collection. Such questionings refer basically to PIS, COFINS, INSS and FGTS contributions. At March 31, 2013, the Company recorded a consolidated amount of R\$218,775 (R\$ 218,210 at December 31, 2012), related to claims classified by its legal advisors as possible loss, for which there were no provisions, according to the accounting rule applicable for those circumstances, substantially R\$159,669 being related to ICMS claims on import of leasing equipment and direct import of inputs and equipment made in the period between EC 33 (issued in December 2001) and Supplementary Law No. 114 (issued in December 2002), and R\$59,086 related to other PIS, COFINS and ISS tax claims.

Notes to the quarterly informationChanges in provisions for contingencies

	Company				
	12/31/12	Changes for the period			03/31/13
	Closing balance	Additions	Utilization and reversal	Monetary Restatement	Closing balance
ICMS on import	96,155	-	-	856	97,011
Provision for labor and civil contingencies	4,182	2,621	(1,466)	-	5,337
Provision for tax contingencies	28,589	4	(179)	128	28,542
	128,926	2,625	(1,645)	984	130,890

	Consolidated				
	12/31/12	Changes for the period			03/31/13
	Closing balance	Additions	Utilization and reversal	Monetary Restatement	Closing balance
ICMS on import	96,155	-	-	856	97,011
Provision for labor and civil contingencies	5,057	2,621	(1,491)	-	6,187
Provision for tax contingencies	31,039	4	(179)	128	30,992
	132,251	2,625	(1,670)	984	134,190

22. Equitya) Share-based payment

At December 7, 2010, the board of directors approved a new stock option plan for our management and employees ("New Plan") and its chief guidelines were then determined on December 16, 2010.

The New Plan was approved at the Special General Meeting held on January 5, 2011. On the same date, a meeting of the board of directors approved the granting of shares under the New Plan and the first stock option program which, among other matters, elected the beneficiaries.

On May 9, 2011, the board of directors approved the election of the beneficiaries of the New Plan, and subject to the terms and conditions determined in the first program, the executive board signed stock option agreements with each of the beneficiaries.

Each beneficiary, having met the conditions stated for the plan will be granted options to acquire or subscribe to a number of registered common shares with no par value corresponding to the percentage of 250% (two hundred and fifty per cent) of own shares (acquired by the beneficiaries). Percentages for each individual beneficiary are defined by the board of directors and stated in the agreement signed with each beneficiary.

Other than the amount invested by the beneficiary for acquisition of treasury shares no other consideration shall be required of the beneficiary to exercise the benefit, and the above price consubstantiates the beneficiary's obligation to acquire the own shares and hold them for a period of three (3) years after acquiring them.

Stock options may only be exercised by beneficiaries, in full or in part, three (3) full years after the date of signing the agreement (*vesting period*).

Notes to the quarterly information

At the end of the vesting period, beneficiaries may exercise their rights in full or in part by giving written notice to the Company within thirty (30) days of the vesting date, subject to specific requirements, dates and periodicities established by the board of directors.

Stock options granted in May 2011

In May 2011, the board entered into stock-option agreements with beneficiaries under the plan. The number initially granted was 309,076 common shares, but currently there are 106,576 (114,775 at December 31, 2012), after canceled agreements and adjustments made to the plan in March 31, 2013, and they are due to vest by May 2014.

At March 31, 2013, the balance recorded under Granted options, in equity, is R\$ 772 (R\$ 814 at December 31, 2012), equivalent to 66,008 common shares (61,660 at December 31, 2012), which correspond to the total amount of granted shares proportionally to the period elapsed of the contracts executed, as follows:

	<u>ON shares</u>	<u>R\$</u>
Balance at December 31, 2012	61,660	814
Cancellations	(4,701)	(64)
Additions	9,049	22
Balance at March 31, 2013	<u>66,008</u>	<u>772</u>

Share-based payment transactions – June 2012

In June 2012, the Company management entered into contracts granting shares to plan beneficiaries. 259,959 common shares were initially granted. Currently this number is 229,410 (240,216 at December 31, 2012) common shares granted considering the contracts cancelled through March 31, 2013, with vesting period up to June 2015.

The balance at March 31, 2013, recorded under Granted Shares, in equity, is R\$ 684 (R\$ 547 at December 31, 2012), equivalent to 58,506 common shares (41,500 at December 31, 2012) corresponding to the total shares granted proportionally to the period elapsed of the contracts executed, as follows:

	<u>Common shares</u>	<u>R\$</u>
Balance at December 31, 2012	41,500	548
Cancellations	(2,259)	(31)
Additions	19,265	167
Balance at March 31, 2013	<u>58,506</u>	<u>684</u>

Notes to the quarterly information

b) Dividends and interest on equity

At the Annual General Meeting held on April 22, 2013, the payment of dividends was unanimously approved for June 20, 2013, as disclosed in the financial statements as of December 31, 2012.

c) Earnings per share

Basic

Basic earnings per share is calculated by dividing income attributable to shareholders by the weighted average number of common shares issued during the period, excluding common shares purchased by the Company and held as treasury shares.

	01/01/2013 up to 03/31/2013	01/01/2012 up to 03/31/2012
Income attributable to Company shareholders	23,522	36,370
Weighted average number of common shares issued	311,803	311,803
Weighted average of treasury shares	(1,159)	(1,159)
Weighted average of outstanding common shares	310,644	310,644
Basic earnings per share - R\$	0.07572	0.11708

Diluted

Diluted earnings per share is calculated by adjusting the weighted average number of common shares outstanding assuming conversion of all common shares that could lead to dilution. The only common shares that could lead to dilution are from stock option plans.

Accumulated for the period	01/01/2013 up to 03/31/2013	01/01/2012 up to 03/31/2012
Income attributable to Company shareholders	23,522	36,370
Weighted average number of outstanding common shares	310,644	310,644
Adjustment for acquisition of shares	336	78
Weighted average number of common shares for diluted earnings per share	310,980	310,722
Diluted earnings per share - R\$	0.07564	0.11705

23. Income and social contribution taxes

a) The Company records monthly provisions for income and social contribution taxes on an accrual basis

Taxes are calculated by taxable income, except for subsidiaries Imagem e Diagnóstico, Multimagem PET and Multi-Imagem Petrópolis, in which it adopted the presumed profit system.

Reconciliation of the expense calculated by applying combined rates for income and social contribution tax expenses charged to income is shown as follows:

Notes to the quarterly information

	Controladora		Consolidado	
	03/31/13	03/31/12	03/31/13	03/31/12
Income before income and social contribution taxes	27,686	44,409	36,280	57,687
Combined tax rate	34%	34%	34%	34%
Income and social contribution taxes:				
At combined rate	(9,413)	(15,099)	(12,335)	(19,614)
Permanent exclusions (additions)				
Equity pickup	5,549	9,389	-	-
Interest on equity	-	(408)	-	-
Non-deductible expenses	(230)	(199)	(250)	(301)
Other adjustments				
Profit (loss) of subsidiary abroad	-	-	(413)	132
Profit computed as a percentage of the Company's gross revenue (Presumed profit system)	-	-	221	196
Other	(70)	(1,722)	57	(1,686)
	(4,164)	(8,039)	(12,720)	(21,273)
- Current income and social contribution taxes	-	-	(8,916)	(9,750)
- Deferred taxes	(4,164)	(8,039)	(3,804)	(11,523)
- Total	(4,164)	(8,039)	(12,720)	(21,273)
Effective rate	-15%	-18%	-35%	-37%

The 34% combined tax rate used for 2013 and 2012 calculations applies to taxable profit for legal entities in Brazil as required by the tax laws of this jurisdiction.

b) Deferred taxes on tax losses and temporary provisions

Income and social contribution taxes are stated so as to reflect future tax effects attributable to temporary differences between the assets and liabilities tax bases and their respective book values.

In accordance with CPC 32, based on the expectation of generating future taxable profit backed by a technical study approved by our management, the Company recognizes tax credits and debits on deductible temporary differences and accumulated tax losses and negative bases for social contribution, which are not subject to limitation and may be used to offset up to 30% of annual taxable profit. The book value for deferred tax assets and liabilities is reviewed quarterly and projections are reviewed annually.

The composition of the balances of deferred income and social contribution taxes assets and liabilities are shown below:

Notes to the quarterly information

	Company balance sheet		Company income
	03/31/13	12/31/12	(expenses) 03/31/13
Income and social contribution tax losses	107,803	98,246	9,557
Allowance for doubtful accounts and disallowances	26,016	25,074	942
Goodwill amortization	280	997	(717)
Provision for specialized medical services	6,506	3,757	2,749
Sundry provisions	2,907	168	2,739
Provision for contingencies	34,609	33,941	668
Amortization of pre-operating expenses	247	329	(82)
Review of property and equipment useful lives	-	-	-
Other	514	514	-
Goodwill amortization	(129,139)	(108,073)	(21,066)
Intangible assets in interest acquisitions	(86,796)	(87,697)	901
Review of property and equipment useful lives	(12,093)	(9,154)	(2,939)
Other	(556)	(3,640)	3,084
Deferred income and social contribution taxes – Assets			
(liabilities)	(49,702)	(45,538)	
Deferred income and social contribution tax revenue (expenses)			(4,164)
Reflected in balance sheets as follows:			
Deferred tax asset	-	-	
Deferred tax liability	(49,702)	(45,538)	
Deferred income and social contribution taxes – asset (liability)	(49,702)	(45,538)	
Reconciliation of deferred tax asset (liability)	03/31/2013		
Balance at December 31, 2012	(45,538)		
Income (expenses) in P&L	(4,164)		
Balance at March 31, 2013	(49,702)		

	Consolidated balance sheet		Consolidated
	03/31/13	12/31/12	income (expenses) 03/31/13
Income and social contribution tax losses	140,381	124,801	15,580
Allowance for doubtful accounts and disallowances	30,344	30,884	(540)
Goodwill amortization	25,085	28,297	(3,212)
Provision for specialized medical services	8,803	6,339	2,464
Sundry provisions	2,919	214	2,705
Provision for contingencies	35,601	34,935	666
Amortization of pre-operating expenses	247	329	(82)
Review of property and equipment useful lives	4,744	4,867	(123)
Other	535	514	21
Goodwill amortization	(130,015)	(109,124)	(20,891)
Intangible assets in interest acquisitions	(92,493)	(93,429)	936
Review of fixed asset useful lives	(13,920)	(11,040)	(2,880)
Other	(6,163)	(7,715)	1,552
Deferred income and social contribution taxes – asset (liability)	6,068	9,872	
Deferred income and social contribution tax revenues (expenses)			(3,804)
Reflected in balance sheets as follows:			
Deferred tax asset	57,604	57,002	
Deferred tax liability	(51,535)	(47,130)	
Deferred income and social contribution tax – asset (liability)	6,069	9,872	
Reconciliation of deferred tax asset (liability)	03/31/2013		
Balance at December 31, 2012	9,873		
Tax revenue (expenses) in P&L	(3,804)		
Balance at March 31, 2013	6,069		

Notes to the quarterly information

Management believes that the balances of deferred income and social contribution tax assets on temporary differences will be realized in proportion to the contingencies and occurrence of the events that gave rise to the provisions for losses.

The Company did not identify any indications of impairment of deferred taxes for the quarter.

24. General and Administrative Expenses by nature

	Company		Consolidated	
	03/31/13	03/31/12	03/31/13	03/31/12
Personnel expenses	40,848	40,308	52,754	48,679
Profit sharing and bonus	7,500	-	7,500	-
Services and utilities	14,377	21,550	22,880	29,818
Depreciation and amortization	13,037	10,465	13,973	12,657
Taxes and fees	3,122	654	3,896	1,155
Sundry provisions	2,420	2,202	2,601	(375)
Allowance for doubtful accounts and write-offs	(32)	16	15	16
General expenses	13,799	12,105	18,480	14,978
	95,071	87,300	122,099	106,928

25. Financial instruments

The Company is generally exposed to the following operating risks that may affect its strategic and financial objectives to a greater or lesser extent:

- market risk
- liquidity risk
- credit risk
- operating risk

The Company manages the risks to which it is exposed by defining conservative strategies to ensure liquidity, profitability, and security, using objective criteria for risk diversification.

This note reports the Company's exposure to each of the above risks, and its objectives, policies and processes for risk measurement and management and for capital management.

Risk management structure

In alignment with current regulations and with the Company's corporate policies, the system is based on the integrated management of each of the business processes and on adjusting risk level to strategic objectives. The Company's corporate governance structure involves an extensive risk management process for identifying, treating, and monitoring these risks that extends from senior management, and institutional committees such as the auditing committee, which is responsible, among other duties, for overseeing the integrity and effectiveness of internal controls and risk management through to all the Company's different areas.

The Company's internal control environment has been designed to support the nature, risk, and complexity of its operations. It is based on formalized policies and procedures that are disseminated throughout the organization, as well as dedicated business areas and specific tools for risk monitoring.

Notes to the quarterly information

Management of all risks inherent to the Company's activities on an integrated basis is addressed within a process supported by the structures of Internal Controls and Compliance (in relation to internal policies, rules, and regulations) that ensures continuous improvement for risk management models and minimizes any omission that could jeopardize correct risk identification and assessment. Based on identification, assessment and monitoring of the principal risks, the Company draws up specific action plans to ensure that improvements are implemented.

To build the right control environment for the scale of its business, the Company invests to strengthen internal communication and disseminate the risk management concept among employees. Corporate risk management is supported by statistical tools with liability adequacy testing, stress testing, capital sufficiency indicators and others. In addition to these tools, the Company adds the qualitative side of risk management, with results from self-assessment, quality evaluations, and tests conducted by internal auditing to evaluate the effectiveness and efficiency of internal controls, as well as quality performance in fulfilling duties and responsibilities.

Historically, the financial instruments used by the Company have shown adequate results for risk mitigation. Additionally, we avoid transactions involving exotic or speculative derivatives.

Market risks

These are risks related to assets and liabilities with cash flows or present values that are exposed to:

- a) *Exchange-rate risk*: Risk of loss or gain depending on fluctuations in prices of foreign currencies. The main tool to control exchange-rate related risk is the daily treasury position, which is based on reports provided by the BM&FBovespa and other sources (e.g. the Central Bank) for the control of exchange-rate variations involved in our operations.
- b) *Market risk - interest*: Risk of fluctuating interest rates leading to increased expenses or decreased income. Fixed interest rates maintained to maturity allow certainty for cash flows. Floating interest rates pose volatility for future interest charges. The main tool for control of risk related to interest rates is the daily treasury position, which is based on reports provided by the BM&FBovespa to control interest rates involved in our transactions.

Our principal market risks arise from possible fluctuations in interest rates and exchange rates. As a result, the Company and its subsidiaries seek hedging for liquidity risk through financial instruments such as marketable securities, funding in the form of working capital loans, and funding through the issue of debentures, all on an arms' length basis, as well as USD-CDI index swaps.

The Company's market risk management practices are based on the operating strategies and internal controls established in its Internal Policy for Risk Management of Financial Assets ("Policy") in order to ensure liquidity, profitability, and security of financial instruments exposed to risk. These practices consist of periodically monitoring its contractual conditions in comparison with current market conditions.

Every financial transaction is submitted to the Executive Committee and subsequent validation by the board of directors and / or their auxiliary advisory committees. In the cases of exchange rate and interest-rate exposure, guidelines are set by the board of directors and operated by the Treasury department, since they depend of variable components of the economic scenario. Treasury forwards a monthly report to the Executive Committee showing the Company's current exposure to market risks and using reports, documents and contracts checks for compliance with the policy.

Notes to the quarterly information

In addition to the above, for market risks to which the Company is exposed, Treasury is mandated to run monthly stress tests assuming 25% and 50% variations in relation to original parameters in order to assess the elasticity of these positions when subjected to major variations of the rates involved in these transactions, and their impact on income and cash positions of the Company.

Liquidity risk

Liquidity risk is the risk of an unforeseeable event or an error in calculating liquidity requirements that will impact the Company's investment decisions or day-to-day business.

We manage liquidity risk by maintaining adequate reserves, bank credit facilities, and credit lines from funding as deemed appropriate, continuously monitoring expected and actual cash flows and the combination of maturity profiles of financial assets and liabilities, following these guidelines:

- a) Short-term cash management - liquid assets and credit facilities to cover immediate needs. Periodicity: Daily. Periodicity: D+1 (working days);
- b) Long-term cash management - Continuous process to ensure long-term funds, through analysis of the cash budget on a monthly basis, updating assumptions made in the budget in accordance with business needs, and comparing actual *versus* estimated performance. Periodicity: Monthly. Term: 5th working day of the month following the report's base date;
- c) Maintenance of minimum cash - Refers to cash balances the Company may replenish in a very short period of time to meet any urgent requirements. In addition, it uses the criterion that cash holdings must be sufficient to cover the five worst daily cash flows in a month, not including receivables;
- d) Exposure limits and risk mitigation - the treasury department keeps short-term facilities for immediate liquidity and working capital lines, so that volume is sufficient to ensure at least the amount equal to that of the highest cash outflow over five consecutive days in the last 12 months.

For medium- and long-term facilities, the treasury department maintains credit lines to match the Company's strategic planning and constantly aims to ensure availability requirements as informed by the management committee.

The following table shows maturity details for consolidated financial liabilities transacted as of March 31, 2013:

Transaction	Consolidated				Total
	Up to 1 year	1 - 2 years	3 - 5 years	Over 5 years	
Derivatives	936	296	151	-	1,383
Trade accounts payables	80,909	-	-	-	80,909
Bank loans and financing	38,794	21,542	11,398	58,062	129,796
Debentures	92,917	294,893	589,919	-	977,729
Taxes in installments	6,349	5,765	6,662	13,462	32,238
Accounts payable for acquisition of subsidiaries	1,618	14,697	48,062	4,128	68,505
	221,523	337,193	656,192	75,652	1,290,560

Notes to the quarterly information*Credit risk*

Refers to the risk of loss resulting from inability of the counterparty to meet its contractual obligations and make payments to the Company. The principal means of mitigating this risk is through the credit analysis process. Measurement of credit risk over time will be based mainly on the determination of the allowance for doubtful accounts.

The Company and its subsidiaries follow the credit policy determined by management to minimize problems arising from default due to disallowances under plans. The Company also set up an allowance for doubtful accounts due to disallowances, default and NSF checks in the parent Company in the amount of R\$ 94,816 (R\$ 91,991 at December 31, 2012) which corresponded to 19.98% (20.59% at December 31, 2012) of outstanding receivables in order to cover credit risk; for the consolidated statements, the corresponding amounts were R\$107,718 (R\$109,220 at December 31, 2012) which amounted to 16.31% (17.97% at December 31, 2012) of outstanding receivable to cover credit risk.

At March 31, 2013, the maximum exposure on the consolidated accounts was R\$722,606 (R\$836,184 at December 31, 2012) related to cash and cash equivalents and receivables.

Operating risk

Operating risk is the risk of direct or indirect loss arising from a variety of causes associated with our personnel, technology and infrastructure processes, as well as external factors, other than credit, market and liquidity risks. It includes risks such as those arising from legal and regulatory requirements and generally accepted standards of corporate conduct. Operational risks arise from all our operations.

The objective of the Company is to manage operating risk to prevent the occurrence of financial losses or damage to its reputation while ensuring cost effectiveness and avoiding control procedures that hamper initiative and creativity.

The primary responsibility for developing and implementing controls to cover operating risk is attributed to senior management. The latter is supported by development of overall standards for operating risk management in the following areas:

- requirements for appropriate segregation of duties, including independent authorization of transactions;
 - requirements for reconciliation and monitoring transactions;
 - compliance with legal and regulatory requirements
 - documentation of controls and procedures;
 - requirements for periodic assessment of operating risks faced, and adequacy of controls and procedures to treat the identified risks;
 - requirements for reporting transaction losses and proposed corrective measures;
 - developing contingency plans;
 - Professional training and development;
 - ethical and business standards;
- risk mitigation, including insurance, when effective

Notes to the quarterly information

Compliance with these standards is supported by a process of continuous quality assessment and a program of periodic reviews undertaken by Internal Auditing. The results of Internal Auditing analyses are discussed with the management of the business unit concerned, and summaries are forwarded to the Auditing Committee and to senior management.

Capital management

The Company monitors financial leverage in order to maintain an appropriate capital structure for the operation and to reduce indebtedness costs. The leverage ratio used corresponds to net debt divided by total equity. The consolidated financial leverage ratios at March 31, 2013 and December 31, 2012 were as follows:

	<u>03/31/2013</u>	<u>12/31/2012</u>
Loans and financing (a)	129,796	147,397
Debentures (a)	977,729	958,984
Derivatives	1,383	1,233
Total gross debt	<u>1,108,908</u>	<u>1,107,614</u>
Cash and cash equivalents and marketable securities in current assets	<u>259,615</u>	<u>260,472</u>
Net debt	<u>849,293</u>	<u>847,142</u>
Equity	2,630,847	2,607,192
Ratio	0.32282	0.32493

(a) Amounts are reported net of transaction costs

The Company may alter its capital structure depending on economic-financial, strategic or operational conditions, in order to improve debt management. At the same time, it aims to improve return on invested capital (ROIC) through working capital management and an efficient investment program.

The Company is subject to maximum indebtedness levels according to the terms presented in Note 17.

Financial instrument by category

The table below shows the Company's financial instruments by category. Fair values of financial instruments shown do not vary significantly from the balances shown in the Company and Consolidated statements of financial position.

Notes to the quarterly information

Description	Company					
	03/31/2013			12/31/2012		
	Fair value through profit/loss	Loans and receivables	Amortized cost	Fair value through profit/loss	Loans and receivables	Amortized cost
Cash and cash equivalent and marketable securities	231,516	-	-	199,349	-	-
Judicial deposits	91,590	-	-	91,117	-	-
Trade accounts receivable	-	379,620	-	-	354,812	-
Assets	323,106	379,620	-	290,466	354,812	-
Trade accounts payables	-	-	51,520	-	-	54,714
Bank loans and financing	-	-	21,590	-	-	28,152
Debentures	-	-	977,729	-	-	958,984
Derivatives	1,383	-	-	1,233	-	-
Taxes in installments	-	-	14,509	-	-	12,392
Accounts payable for acquisition of subsidiaries	-	-	57,494	-	-	58,600
Liabilities	1,383	-	1,122,842	1,233	-	1,112,842
Description	Consolidated					
	03/31/2013			12/31/2012		
	Fair value through profit/loss	Loans and receivables	Amortized cost	Fair value through profit/loss	Loans and receivables	Amortized cost
Cash and cash equivalents and marketable securities	317,474	-	-	318,107	-	-
Judicial deposits	95,735	-	-	95,274	-	-
Trade accounts receivable	-	552,888	-	-	498,455	-
Assets	413,209	552,888	-	413,381	498,455	-
Trade accounts payables	-	-	80,909	-	-	84,429
Bank loans and financing	-	-	129,796	-	-	147,397
Debentures	-	-	977,729	-	-	958,984
Derivatives	1,383	-	-	1,233	-	-
Taxes in installments	-	-	32,238	-	-	32,830
Accounts payable for acquisition of subsidiaries	-	-	68,505	-	-	69,432
Liabilities	1,383	-	1,289,177	1,233	-	1,293,072

Fair value hierarchy

The Company only holds level-2 financial instruments corresponding to marketable securities on a consolidated basis of R\$306,094 at March 31, 2013 (R\$302,020 at December 31, 2012) and derivatives on a consolidated basis in the amounts of R\$1,383 at March 31, 2013 (R\$1,233 at December 31, 2012).

The different levels are defined as follows:

- Level 1 - Prices (not adjusted) quoted in active markets for identical assets and liabilities.
- Level 2 - Inputs, other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (prices) or indirectly (derived from prices).
- Level 3 - Assumptions for the asset or liability that are not based on observable market data (unobservable inputs).

Notes to the quarterly informationa) *Estimated fair values*

Estimated fair value for financial instruments was developed using a pricing model applied individually to each transaction, taking into account future payment flows based on contractual terms, discounted to present value at rates obtained through the market interest curve, based on information obtained from the BM&FBovespa and ANBIMA websites.

Therefore a security's fair value corresponds to its value at maturity (redemption value) brought to present value using a discount factor (related to the maturity date) obtained from the market interest curve in *Reais*.

b) *Derivatives*

The hedge instruments contracted by the Company are non-deliverable forwards and interest rate swaps with no leverage component, margin call clause, daily adjustment or periodic adjustments. The assumptions used for calculation of assets and liabilities are broken down in the table below:

At March 31, 2013, the Company held the following swaps:

Financial instruments - Derivatives payable (Consolidated)

Company Strategy	Asset Index	Fair value (book value)						Currency/ index	Maturity range	Notional	Trading Market	Counter party
		Asset	Liability Index	Liability	Fair value	Values at cost	Fair value calculation gain (loss)					
Derivatives for hedging debts not designated at fair value												
Swap - FX hedge	USD	14,708	78,55% of CDI	(16,091)	(1,383)	(2,308)	925	USD	04/2010 - 03/2016 *	7,412	Counter	Banco HSBC
		<u>14,708</u>		<u>(16,091)</u>	<u>(1,383)</u>	<u>(2,308)</u>	<u>925</u>					
Classified in Current liabilities					(936)							
Classified in Non-current liabilities					(447)							

* Monthly maturity

The Company recognized gains and losses on its derivative instruments. However, since they are hedging derivatives, these gains and losses minimized the impact of exchange-rate and interest-rate variation incurred by the indebtedness that the derivatives were hedging. At March 31, 2013, derivative instruments had the following impacts on consolidated income:

Derivatives	Risk	Account	Revenue (Expense)	
			03/31/13	12/31/12
Banco HSBC (SWAP)	Exchange-rate variation interest – adjustment to fair value	Financial income/ (expenses)	<u>(623)</u>	<u>(1,400)</u>
			<u>(623)</u>	<u>(1,400)</u>

Notes to the quarterly informationSensitivity analysis of derivatives

The Company carried out the sensitivity analysis for the main risks to which its financial instruments (including derivatives) are exposed, which basically refer to risks related to exchange and interest rate variations, as follows:

Exchange-rate variation

Fair value was calculated in accordance with projections made on the date of this quarterly financial information for future quotations of the US dollar obtained from BM&FBovespa. In the case of the scenarios, as determined by the abovementioned instruction, the stress percentages defined therein were added.

Assuming the notional exposure of quarterly information indexed to variable interest rates above are maintained, the effects of dollar depreciation on the Company's consolidated quarterly financial information, by type of financial instrument, for the two different scenarios, would be as follows:

Contracts	Risk	Exposure	Fair value at 03/31/2013	Depreciation 25%	Depreciation 50%
Contract SWAP – HSBC Asset position - Exchange-rate variation	Dollar depreciation- US\$	7,412	14,708	(3,677)	(7,354)
		7,412	14,708	(3,677)	(7,354)

Interest-rate variation

Fair value was calculated in accordance with the projections on the date of this quarterly financial information for future quotations for each maturity date of principal and interest obtained on the BM&FBovespa. In the case of the scenarios, as determined by the abovementioned instruction, the stress percentages defined therein were added.

Assuming the exposure of financial instruments indexed to variable interest rates at March 31, 2013 is maintained, the effects of a higher interbank (CDI) on the Company's consolidated quarterly financial information, by type of financial instrument, for two different scenarios, would be as follows:

Contracts	Risk	Exposure	Fair value at 03/31/2013	Increase 25%	Increase 50%
SWAP - HSBC Liability position - Interest	Increase of CDI	7,412	14,708	(3,677)	(7,354)
		7,412	14,708	(3,677)	(7,354)

Sensitivity analysis of financial assets and liabilities

The principal risks concerning the Company's operations relate to interbank (CDI) rate variations for promissory notes, debentures and short-term investments linked to the dollar exchange rate variation for senior notes and marketable securities.

Notes to the quarterly information

CDI Investments are recorded at fair value, in accordance with quotations disclosed by the corresponding financial institutions and the others refer mostly to banking deposit certificates and repurchase agreements, therefore the amount recorded for these securities shows no difference in relation to fair value.

Based on expectations disclosed by the Central Bank report (FOCUS/Bacen), the projections obtained for the next 12 months averaged 7.83% for the CDI and R\$2.00 for the exchange-rate (R\$/US\$).

In order to verify the sensitivity of the index for our marketable securities on the base date of March 31, 2013, three different scenarios were defined based on the projection, from which variations of 25% and 50% were calculated.

For each scenario gross financial expense / (income) was calculated, not including the impact of taxes and the flow of maturities of each contract scheduled for 2012.

Transaction	Balance at 03/31/2013	Risk	Scenario I		
			(Probable)	Scenario II	Scenario III
Marketable securities	31,296	USD	214	7,824	15,648
Rate subject to variation			2.00	1.51	1.01

In order to verify the sensitivity of the index for our debts on the base date of March 31, 2013, three different scenarios were defined based on the projection, from which variations of 25% and 50% were calculated.

Gross financial expenses / (income) were calculated for each scenario, not including the impact of taxes and the flow of maturities of each contract scheduled for 2012.

Gross financial expense was calculated for each scenario, not taking into consideration the impact of taxes and the flow of maturities of each contract scheduled for 2012. The base-date used for financing was March 31, 2013, projecting indices for one year and finding their sensitivity in each scenario.

Transaction	Balance at 03/31/2013	Risk (a)	Scenario I		
			(Probable)	Scenario II	Scenario III
Debentures	981,670	CDI	76,865 7.83%	96,081 9.79%	115,297 11.75%
Working capital	25,06	CDI	2,021 7.83%	2,526 9.79%	3,031 11.75%
(Senior Notes)	60,055	USD	(412) 2.00	15,014 2.52	30,027 3.02

(a) Rate may vary

Notes to the quarterly informationFair value

	Company			
	03/31/2013		12/31/2012	
	Book value	Fair value	Book value	Fair value
<u>Assets</u>				
Marketable securities	223,917	223,917	186,680	186,680
Judicial deposits	91,590	91,590	91,117	91,117
Trade accounts receivable	379,620	379,620	354,812	354,812
<u>Liabilities</u>				
Trade accounts payable	51,520	51,520	54,714	54,714
Debentures	977,729	973,304	958,984	962,649
Derivatives	1,383	1,383	1,233	1,233
Loans and financing:				
Other bank loans	21,590	21,590	28,152	28,152
<u>Consolidated</u>				
	03/31/2013		12/31/2012	
	Book value	Fair value	Book value	Fair value
<u>Assets</u>				
Marketable securities	306,094	306,094	302,020	302,020
Judicial deposits	95,735	95,735	95,347	95,347
Trade accounts receivable	552,888	552,888	498,455	498,455
<u>Liabilities</u>				
Trade account payables	80,909	80,909	84,429	84,429
Debentures	977,729	973,304	958,984	962,649
Derivatives	1,383	1,383	1,233	1,233
Loans and financing:				
Loan - Banco do Brasil	25,789	25,789	28,669	28,753
Notes (<i>Senior Notes</i>)	60,055	62,010	59,652	64,020
Other bank loans	43,952	43,952	59,076	59,076
	129,796	131,751	147,397	151,849

26. Related parties

During the periods ended March 31, 2013 and 2012, the Company entered into transactions with related parties within its normal operating context, as shown below:

Notes to the quarterly informationa) Transactions related to services rendered between Company and related parties

<u>Balance at the end of the period</u>	<u>03/31/13</u>	<u>12/31/12</u>
Current assets - Customers		
CientificaLab	2,223	3,396
CERPE	53	162
Cytolab	1	6
Previlab	157	979
	<u>2,434</u>	<u>4,543</u>
Current liabilities – Other accounts payable		
DASA RE (i)	192	184
Sérgio Franco (ii)	4,292	2,242
	<u>4,484</u>	<u>2,426</u>
	<u>03/31/13</u>	<u>12/31/12</u>
Income (loss) for the period		
Revenue from services		
CientificaLab	1,242	521
CERPE	149	215
Previlab	275	10
Cytolab	-	18
	<u>1,666</u>	<u>764</u>
Costs of services rendered		
DASA RE (i)	388	448
CientificaLab (ii)	-	15
Sérgio Franco (ii)	4,898	4,040
	<u>5,286</u>	<u>4,503</u>

(i) Amounts corresponding to property rent.

(ii) Amounts corresponding to clinical analysis services.

Transactions with related parties, as shown above, are carried out at cost and eliminated in the consolidated quarterly information.

b) Advance for future capital increase and loan

	<u>03/31/2013</u>	<u>12/31/2012</u>
CientificaLab Produtos Laboratoriais e Sistemas Ltda.	4,000	15,500

c) Management compensation

Total management compensation including fixed amounts and bonuses, was R\$ 666 on 2013 first quarter and R\$ 756 on 2012 first quarter, which was paid to members of the board of directors (which had 5 members in both first quarter 2013 and 2012), and \$1,338 on the 2013 first quarter and R\$2,312 on 2012 first quarter paid to statutory directors (there was an average of 9 statutory directors in first quarter 2013 and 13 in the first quarter 2012).

Notes to the quarterly information

Share-based payment is disclosed in Note 22. There were no additional benefits for the Company's management members.

- d) Balances of contracts between subsidiaries at March 31, 2013. These balances are not shown in the quarterly financial information since they do involve the parent Company and are eliminated in the consolidated statements.

Lender	Borrower	03/31/13	12/31/12	Maturity	Rate
Pro Echo	Sérgio Franco	34,318	33,772	10/25/2016	100% CDI
Pro Echo	CDPI	31,589	22,502	11/07//2017	100% CDI
Pro Echo	Check-Up	2,989	2,829	12/17/2017	CDI + 1.6% p.a.
Pro Echo	Previlab	5,501	5,392	09/23/2017	CDI + 1.6% p.a.
Pro Echo	CientificaLab	7,158	7,045	11/08/2017	100% CDI
Pro Echo	Multi-Imagem	2,161	2,127	05/30/2017	100% CDI
Pro Echo	CERPE	2,379	614	12/26/2017	CDI + 1.6% p.a.
		86,095	74,281		

Other transaction with related parties

Link Consultoria em Medicina Diagnóstica Ltda: a Company controlled by Alcione Moya Aprilante, shareholder in Previlab Análises Clínicas Ltda., a subsidiary of the Company that renders services based on fixed remuneration, including regional consultancy services specialized in management of companies in the medical sector, with marketing expertise, relationships with physicians in the region where Previlab is active, and recognition of prospective healthcare professionals and customers.

- Medparts Participações e Negócios Ltda.: entity controlled by Doctor Luciano Flávio Freitas de Almeida, member of Instituto de Endocrinologia e Medicina Nuclear do Recife Ltda. – CERPE, which renders services to the Company, providing advisory services on business management of medical companies, with market know-how, relationship with local physicians, and recognition of potential professionals and customers in healthcare field.
- Melania Angelieri Cunha Aprilante: spouse of Doctor Alcione Moya Aprilante, member of Previlab Análises Clínicas Ltda., owner of properties leased by Previlab, which is an entity controlled by the Company, located at:

Rua. Alferes José Caetano, nº 563	Piracicaba	SP
Rua 15 de novembro, nº 1120	Capivari	SP
Rua Presidente Roosevelt, nº 755	Limeira	SP
Av. Brasil, nº 499	Americana	SP
Rua Acácio do Canto, nº 189	Piracicaba	SP
Rua Maceió, nº 242	Piracicaba	SP
Rua Floriano Peixoto, nº 940	São Pedro	SP

Notes to the quarterly information

- César Antonio Biazio Sanches: member of Análises Clínicas Ltda., owner of the property leased by Previlab, which is an entity controlled by the Company, located at Rua Alferes Franco, nº 408 – Limeira, SP.
- A e C Consultores Ltda.: a Company controlled by Cezar Antonio Biázio Sanches, shareholder in Previlab Análises Clínicas Ltda., a subsidiary of our Company, that renders services based on fixed remuneration, including consulting and business advisory services in the area of activities of Previlab as well as services involving consulting engagements, and the instruction, training and evaluation of professionals for Previlab's workforce and its service providers.
- Pesmed – Pesquisas e Serviços Médicos Ltda: a Company controlled by Mr. Emerson Leandro Gasparetto, our radiology and graphical methods officer (elected March 26, 2012) and his wife, also a medical professional, Dr. Taisa Pallu Davaus Gasparetto, for consulting services in the form of medical research and surveys for subsidiaries: CDPI – Clínica de Diagnósticos por Imagem Ltda, CRMI – Clínica de Ressonância e Multi Imagem Ltda. The amounts are calculated based on the number of reports actually prepared by Pesmed, with due regard for the amount corresponding to each type of report, as per the list prepared by Company, using the same system adopted for the other providers of services for the Company, on an arms' length basis.
- Lockall da Informática e Suprimentos Ltda – ME: Company of the spouse of Claudia Cohn, managing officer of brand Alta, which provides infrastructure and IT services.
- Contract - RMR Ressonância Magnética Ltda: a Company with shareholders jointly holding 33.24% of its capital who are the brothers of Mr. Romeu Cortês Domingues, chairman of the board of directors of the company (elected April 26, 2011) , which provides medical services in the field of magnetic resonance imaging for these subsidiaries: CDPI – Clínica de Diagnósticos por Imagem Ltda; CRMI – Clínica de Ressonância e Multi Imagem Ltda; and Clínica de Ressonância e Multi-Imagem Caxias Ltda. Amounts are calculated based on revenue from magnetic resonance imaging services and numbers of exams produced by RMR, recognizing the corresponding charge for each type of report, as per the list prepared by the Company and using the same system adopted for the other providers of services for the Company, on an arms' length basis.

Amounts paid for services rendered by the above companies for the periods ended at March 31, 2013 and 2012 were as follows:

Contractor	Principal	03/31/13	12/31/12
Link Consultoria em Medicina Diagnóstica Ltda.	Previlab	47	-
A e C Consultoria Ltda.	Previlab	99	-
Pesmed – Pesquisa e Serviços Médicos Ltda.	CDPI	76	89
Pesmed – Pesquisa e Serviços Médicos Ltda.	CRMI	23	23
RMR Ressonância Magnética Ltda.	CDPI	483	277
RMR Ressonância Magnética Ltda.	CRMI	412	409
RMR Ressonância Magnética Ltda.	CRMI Caxias	18	17
Medparts Participações e Negócios Ltda.	DASA	61	-
Melania Angelieri Cunha Aprilante	Previlab	66	-
César Antonio Biazio Sanches	Previlab	21	-
Lockall da Informática e Suprimentos Ltda – ME:	DASA	28	-

Notes to the quarterly information**27. Leases**Local currency leases

The Company is a lessee of assets recognized in Property and Equipment with purchase options for which the total balance payable through 2015 amounts to R\$30,801 for the consolidated accounts, of which R\$15,632 is classified in current liabilities and R\$15,169 in non-current liabilities. The average term of the contracts is 36 months and they bear interest rates ranging from CDI + 1.18% to CDI + 2.10% p.a.

Future minimum payments under loans and financing (see Note 16) are segregated as follows:

	03/31/2013					
	Company			Consolidated		
	Present value of minimum payments	Interest	Minimum future payments	Present value of Minimum payments	Interest	Minimum future payments
Up to 1 year	3,986	121	4,107	13,198	402	13,600
1-5 years	3,306	101	3,407	11,670	354	12,024
	7,292	222	7,514	24,868	756	25,624

	12/31/2012					
	Parent			Consolidated		
	Amount Present value payments minimum	Interest	Payments futures minimum	Amount Present value payments minimum	Interest	Payments Futures Minimum
Up to 1 year	4,205	176	4,381	15,632	653	16,285
1-5 years	4,041	169	4,210	15,169	634	15,803
	8,246	345	8,591	30,801	1,287	32,088

The assets listed below are included in the property and equipment for the Company and its subsidiaries.

Net book values of assets acquired through local financial leases are:

	Company		Consolidated	
	03/31/13	12/31/12	03/31/13	12/31/12
Machinery and equipment	6,960	7,560	19,606	20,391
Furniture and fixtures	43	48	48	62
Vehicles	-	1	50	42
IT Equipment	651	694	901	1,052
Property and equipment in progress	2	-	25	-
Facilities	-	70	1,018	68
IT System	65	3	65	30
	7,721	8,376	21,713	21,645

Notes to the quarterly informationForeign lease

The Company leases equipment used to provide services under lease agreements with purchase options. Payment is made in 84 months, with an agreed grace period of 6 months before payment of the first installment, and the remaining installments being paid on a quarterly and semi-annual basis. Quarterly and semi-annual installments in US dollars are translated into Brazilian *Reais* at the dollar's market exchange rate on the payment date, plus interest ranging from 7.20% to 9.00% p.a., making for a total balance payable through 2016 of R\$24,718, of which R\$14,346 is classified in current liabilities and R\$10,372 in non-current liabilities.

Future minimum payments are segregated as follows:

	03/31/2013					
	Company			Consolidated		
	Amount Present value payments		Payments future	Amount Present value payments		Minimum future payments
	minimum	Interest	minimum	minimum	Interest	
Up to 1 year	9,697	622	10,319	11,035	707	11,742
1-5 years	4,601	295	4,896	5,694	365	6,059
	14,298	917	15,215	16,729	1,072	17,801

	12/31/2012					
	Company			Consolidated		
	Present value of minimum payments	Interest	Minimum future payments	Present value of minimum payments	Interest	Minimum future payments
Up to 1 year	11,384	747	12,131	12,984	852	13,836
1-5 years	7,271	477	7,748	8,403	552	8,955
	18,655	1,224	19,879	21,387	1,404	22,791

Foreign lease agreements are included in property and equipment under machinery and equipment', with R\$59,765 (R\$53,800 at December 31, 2012) for the parent Company and R\$80,523 (R\$72,507 at December 31, 2012) for the consolidated statements.

28. Net revenue

The following table shows reconciliation between gross revenue for tax purposes and revenue shown in the statement of income for the period:

	Company		Consolidated	
	03/31/13	12/31/12	03/31/13	12/31/12
Gross revenue	457,436	435,253	640,412	609,544
Deductions:				
Taxes	(26,165)	(25,624)	(35,870)	(36,136)
Allowance for loss due to disallowances and default	(16,901)	(16,231)	(20,535)	(15,902)
Discounts	(2,168)	(575)	(2,420)	(813)
	412,202	392,823	581,587	556,693

Notes to the quarterly information**29. Financial Income**

	Company		Consolidated	
	03/31/13	12/31/12	03/31/13	12/31/12
Financial expenses				
Interest	(21,587)	(28,566)	(24,562)	(33,890)
Monetary exchange variation losses	(1,302)	(6,647)	(1,160)	(7,250)
Other	(2,042)	(7,002)	(3,325)	(7,822)
	(24,931)	(42,215)	(29,047)	(48,962)
Financial income				
Interest	3,641	3,254	5,258	8,011
Monetary and exchange variation gains	1,408	6,901	1,746	8,384
Other	127	-	1,049	132
	5,176	10,155	8,053	16,527
	(19,755)	(32,060)	(20,994)	(32,435)

30. Subsequent eventsElection of the Board of Directors

The Annual General Meeting (AGM) held on April 22, 2013, by majority of votes of the attending shareholders and in accordance with the voting system set out in paragraph 5 of Article 17 of the Company's Articles of Association, approved the candidates presented by Management on April 4, 2013, with the subsequent election of the Board of Directors, as follows: (a) Romeu Côrtes Domingues, Chair of the Board of Directors; (b) Oscar de Paula Bernardes Neto, Vice Chair of the Board of Directors; (c) Dickson Esteves Tangerino, Board member; (d) Carlos Fernando Costa, Board member; (e) Maurício Bittencourt Almeida Magalhães, Board member. Pursuant to the second paragraph of Article 17 of the Company's charter and the BM&FBOVESPA Novo Mercado Listing Regulation, Officers Oscar de Paula Bernardes Neto, Carlos Fernando Costa and Maurício Bittencourt Almeida Magalhães are considered independent under *Novo Mercado* ('New Market') Listing regulation.

Statutory reform and set up of the Audit Committee

The Special General Meeting (SGM) held on April 22, 2013 changes the Company's charter and approved the set up of the Statutory Audit Committee (CAE) under the terms of CVM Rule No. 308/99, amended by CVM Rule No. 509/2011.

Election of the Management Board

The Board of Directors' Meeting held on April 22 decided– without any qualifications – to reelect the Company's Management Board members, with a unified term of office up to the AGM approving the accounts for the year ended December 31, 2015. The respective Management members are: (a) CEO: Mr. Dickson Esteves Tangerino; (b) VP Chief Operating Officer: Octávio Fernandes da Silva Filho; (c) VP Business Officer: Mr. Antonio Carlos Gaeta; (d) Chief Investors Relation Officer: Mr. Paulo Bokel Catta-Preta; (e) VP and CFO: Mrs. Cynthia May Hobbs Pinho; (f) Chief Personnel Officer: Mr. Marcelo Rucker; (g) Chief Account and Infrastructure Officer: Mr. Carlos Elder Maciel de Aquino; (h) Chief Radiology and Graphic Methods Officer: Mr. Emerson Leandro Gasparetto; (i) Legal Officer: Mrs. Lilian Cristina Pacheco Lira.

Notes to the quarterly informationStatutory Audit Committee (CAE)

At the Board of Directors' Meeting held on April 22, 2013, the CAE members were elected for as 10 (ten) year term of office: (i) Mr. Raimundo Lourenço Maria Christians; (ii) Mr. Maurício Bittencourt Almeida Magalhães, (iii) Mr. Raphael Nascimento Diederichsen; and (iv) Mrs. Manuela Cristina Lemos Marçal.

São Paulo State Installment Payment Program (PEP)

São Paulo State Decree No. 58811/12 created a special State VAT (ICMS) payment program providing for elimination of 75% of fines and 60% of interest upon cash payment referring to ICMS debts, with a potential 45% additional reduction on fines in case of debts claimed but not under the federally enforceable debt, and a 5% reduction on attorney's fees in case of federally enforceable debts.

Considering these favorable conditions, the Company elected to enjoy these benefits and adhered to the program from May 6 to May 10 to pay off its debts not yet claimed, considered of probable risk by our legal counsel, and which are the subject of Injunction Relief No. 0046827-27.2011.8.26.0053, therefore eliminating tax contingencies referring to ICMS on imports and recorded under provision accounts for judicial deposits (Note 21).

The Company elected to pay ICMS debts in full, amounting to R\$ 38,213 (already with the benefits set out by the referred to Decree).

Dickson Esteves Tangerino
CEO

Paulo Bokel Catta-Preta
Diretor de Relações com Investidores

Cynthia May Hobbs Pinho
Diretora Vice Presidente e Financeira

Daniel Vendramini da Silva
TC-CRC 1SP125812/O-1

Independent auditor's review report on quarterly financial information

The Board of Directors, Shareholders and Officers
Diagnósticos da América S.A.

Introduction

We have reviewed the accompanying individual and consolidated interim financial information contained in the Quarterly Information Form (ITR) of Diagnósticos da América S.A. ("Company") and subsidiaries for the quarter ended March 31, 2013, comprising the balance sheet as of March 31, 2013 and the related statement of income, changes in equity and cash flows for the three months period then ended, including the explanatory notes.

Management is responsible for the preparation of the individual interim financial information in accordance with CPC 21 (R1) - Interim Financial Reporting, and consolidated interim financial information in accordance with CPC 21 (R1) and IAS 34 - Interim Financial Reporting, issued by the International Accounting Standards Board (IASB), as well as for the fair presentation of this information in conformity with the standards issued by the Brazilian Securities and Exchange Commission (CVM) applicable to the preparation of Quarterly Information (ITR). Our responsibility is to express a conclusion on this interim financial information based on our review.

Scope of review

We conducted our review in accordance with Brazilian and International Standards on Review Engagements (NBC TR 2410 and ISRE 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity, respectively). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with auditing standards and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion on the individual interim financial information

Based on our review, nothing has come to our attention that causes us to believe that the individual interim financial information included in the quarterly information referred to above is not prepared, in all material respects, in accordance with CPC 21 (R1) applicable to the preparation of the Quarterly Information (ITR), and presented consistently with the standards issued by the Brazilian Securities and Exchange Commission (CVM).

Conclusion on the consolidated interim financial information

Based on our review, nothing has come to our attention that causes us to believe that the consolidated interim financial information included in the quarterly information referred to above is not prepared, in all material respects, in accordance with CPC 21 (R1) and IAS 34 applicable to the preparation of the Quarterly Information (ITR), and presented consistently with the standards issued by the Brazilian Securities and Exchange Commission (CVM).

Other matters

Statements of value added

We also reviewed the individual and consolidated statements of value added (SVA), for the three-month period ended March 31, 2013, prepared under the responsibility of Company management, whose presentation in the interim financial information is required by the standards issued by the Brazilian Securities and Exchange Commission (CVM) applicable to preparation of Quarterly Information (ITR) and considered supplementary information under IFRS, which do not require SVA presentation. These statements were submitted to the same review procedures previously described and, based on our review, nothing has come to our attention that would make us believe that they were not prepared, in all material respects, in accordance with the overall individual and consolidated interim financial information.

São Paulo, May 13, 2013.

ERNST & YOUNG TERCO
Auditores Independentes S.S.
CRC-2SP015199/O-6

Antonio Carlos Fioravante
Accountant CRC-1SP184.973/O-0

Opinions and Statements/Statement of Officers on the Financial Statements

Observing the provision of article 25 of Ruling No. 480/09 of December 7, 2009, the Board represents that it has reviewed, discussed and agreed with the Quarterly information (Company and Consolidated) for the three month period ended March 31, 2013.

Barueri, May 13, 2013.

CEO - Dickson Esteves Tangerino

Investor Relations Officer - Paulo Bokel Catta-Preta

CFO - Cynthia May Hobbs Pinho

Opinions and Declarations/Statement of Officers on the Independent Auditors Report

In compliance with the provisions of article 25, Instruction # 480/09, of December 7, 2009, the Staff of Officers represents that it has reviewed, discussed and agreed with the opinion expressed in the Independent Auditors' Opinion, dated May 13, 2013, related to the quarterly information (Company and Consolidated) for the period ended on March 31, 2013.

Barueri, May 13, 2013.

CEO - Dickson Esteves Tangerino

Investor Relations Officer - Paulo Bokel Catta-Preta

CFO - Cynthia May Hobbs Pinho